What the evidence says about CRPS, trigeminal neuralgia, and post-herpetic neuralgia By Yoon Hang Kim, MD, MPH Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician About Dr. Kim Dr. Kim is board-certified in Preventive Medicine with more than 20 years of experience in integrative and functional medicine. He completed the University of Arizona fellowship under Dr. Andrew Weil, holds UCLA medical acupuncture certification, and has served as Enterprise Medical Director at WellMed/Optum, Medical Director of Integrative Oncology at Miami Cancer Institute, Director of the Integrative Medicine Program at the University of Kansas Medical Center, and Dean at AIMC Berkeley. His focus includes LDN, autoimmune conditions, chronic pain, integrative oncology, fibromyalgia, chronic fatigue, MCAS, and mold toxicity. He is the author of 8 books and more than 25 peer-reviewed articles, and he founded the LDN Support Group. Professional: www.yoonhangkim.com | Clinical: www.directintegrativecare.com Why nerve pain is so hard to treat Some pain is simple. You twist an ankle, the tissue heals, and the pain fades. Nerve pain doesn't follow that script. Long after the original injury, infection, or inflammation has settled, the nervous system can stay stuck in a high-alert mode. A light touch burns. A breeze on the face sets off lightning. The alarm keeps ringing, even though the fire is out. Clients living with this kind of pain often hear that it's "all in your head." It isn't. The pain is real, and it's being maintained by real biology: overactive immune cells in the spinal cord and brain, weakened braking signals, and a sensory system that has turned up its own volume. That's the territory where low-dose naltrexone (LDN) has drawn so much interest. How LDN might work Naltrexone at standard doses is an opioid blocker. At very low doses, the thinking goes, it does something different. There are two main ideas. Calming microglia. Microglia are the immune cells of the nervous system. When they stay activated, they release inflammatory signals that amplify pain. Lab and animal work suggests naltrexone can quiet this process through Toll-like receptor 4 (TLR4), partly independent of the opioid receptors [8-10]. Boosting the body's own opioids. A brief nightly blockade may prompt the body to make more endogenous opioids, which could strengthen its natural pain-dampening pathways [8]. A fair caution: the TLR4 story is strongest in cells and animals. Whether ordinary oral LDN doses do this meaningfully in people hasn't been proven. It's a leading hypothesis, not settled fact. What the human evidence shows Here is where I want to be careful, because this field attracts more enthusiasm than data. The support varies a lot from one condition to the next. Painful diabetic neuropathy: This is the best evidence we have. In a randomized, double-blind crossover trial of 67 people, LDN relieved pain about as well as amitriptyline, with far fewer side effects (8 adverse events versus 52) [1]. There was no placebo arm and the treatment periods were short, so it shows LDN is active and well tolerated, not that it's better than standard care. Mixed neuropathic pain: A matched retrospective cohort found an average pain reduction of about 38% with LDN versus about 4% in controls. Smaller retrospective series, including one in neuropathic corneal pain, point the same direction [4-6]. These are encouraging but nonrandomized, so selection and expectation effects can't be ruled out. CRPS: The disease-specific evidence is three case reports (two adults, one child) plus subgroup findings from a pain-center series in which 9 of 12 CRPS clients reportedly responded. Every case involved other treatments too [2,4,7,14]. Two placebo-controlled trials, at Stanford and the Hospital for Special Surgery, are underway, but neither has established efficacy yet [23,24]. Trigeminal neuralgia: No completed human randomized trial exists for classical trigeminal neuralgia. Rat studies show LDN reversing facial allodynia [11,12], and a small 2025 human series found lower pain scores in post-traumatic trigeminal neuropathic pain [3]. That is a different condition from classical TN, which is usually driven by blood vessel compression of the nerve. It's an interesting signal, not proof. Post-herpetic neuralgia (PHN): Honestly, there isn't a persuasive human study. An FDA orphan-drug designation exists [28], but that's a regulatory status, not evidence that it works. Applying LDN to PHN is a reasonable hypothesis, since PHN has burning pain and allodynia, but it remains unproven. Who might be worth a closer look No test can predict who will respond. Still, the clients where LDN seems most reasonable to consider tend to share a few features: Allodynia or hyperalgesia out of proportion to any ongoing tissue damage Pain that has spread beyond a single injured area Overlap with CRPS, fibromyalgia, small-fiber symptoms, or dysautonomia Poor tolerance of sedating nerve-pain medications No need for opioid pain medication Think of these as educated guesses, not validated predictors. Safety and what to know before starting LDN is generally well tolerated. The most common complaints are vivid dreams, trouble sleeping, headache, and mild stomach upset, and they often ease with time. The big issue is opioids. Naltrexone is contraindicated with opioid pain medicines, methadone, and buprenorphine, and it can trigger withdrawal [26,27]. It can also blunt opioid-containing cough and antidiarrheal products and complicate pain control around surgery or emergencies. People with significant liver disease need individual review. Dosing is individualized, usually starts low, and rises gradually. Published studies use a fairly narrow low-dose range, but there's no proven best dose for any specific condition. For detailed dosing guidance and the underlying clinical evidence, please visit ifmsynergy.com. Benefit, when it comes, often takes one to three months to show up. A sensible trial sets goals in advance: average and worst pain scores, function (eating, speaking, walking, working), sleep, and a simple overall rating of change at 8 to 12 weeks. If there's no meaningful benefit after an adequate trial, that's a good reason to stop. The bottom line LDN has a credible rationale and a growing, but still modest, clinical signal in nerve pain. It looks most promising for painful diabetic and mixed neuropathic pain, is suggestive but very low-certainty for CRPS, is preclinical or observational for trigeminal pain, and is unproven for post-herpetic neuralgia. So LDN is best thought of as an off-label adjunct, not a replacement for proven care. Classical trigeminal neuralgia still starts with carbamazepine or oxcarbazepine and a proper imaging workup [19,20]. PHN still starts with gabapentinoids, tricyclics, and topical options [21,22]. CRPS still centers on early rehabilitation and multidisciplinary care [18]. If you're living with nerve pain and considering LDN, talk with a clinician who can review your full history, your medications, and your goals. Important: This article is for educational purposes only and is not medical advice. Low-dose naltrexone is used off-label for these conditions. Do not start, stop, or change any medication without talking with your own healthcare provider. References Primary clinical studies 1. Srinivasan A, Dutta P, Bansal D, Chakrabarti A, Bhansali AK, Hota D. Efficacy and safety of low-dose naltrexone in painful diabetic neuropathy: A randomized, double-blind, active-control, crossover clinical trial. Journal of Diabetes. 2021;13(10):770-778. doi:10.1111/1753-0407.13202. PMID: 34014028. [link] 2. Chopra P, Cooper MS. Treatment of Complex Regional Pain Syndrome (CRPS) Using Low Dose Naltrexone (LDN). Journal of Neuroimmune Pharmacology. 2013;8(3):470-476. doi:10.1007/s11481-013-9451-y. [link] 3. Ananthan S, Heir G, Korczeniewska O. Use of low-dose naltrexone in the management of posttraumatic trigeminal neuropathic pain: A retrospective case series. Quintessence International. 2025;56(8):682-690. doi:10.3290/j.qi.b6335903. PMID: 40590142. [link] 4. McKenzie-Brown AM, Boorman DW, Ibanez KR, Agwu E, Singh V. Low-Dose Naltrexone (LDN) for Chronic Pain at a Single Institution: A Case Series. Journal of Pain Research. 2023;16:1993-1998. doi:10.2147/JPR.S389957. [link] 5. Dieckmann G, Ozmen MC, Cox SM, Engert RC, Hamrah P. Low-dose naltrexone is effective and well-tolerated for modulating symptoms in patients with neuropathic corneal pain. The Ocular Surface. 2021;20:33-38. doi:10.1016/j.jtos.2020.12.003. 6. Corser-Jensen CE, et al. Retrospective Analysis of Naltrexone for Persistent Neuropathic Pain: Case Series. Pain Medicine Case Reports. 2023;7:377-383. 7. Soin A. Management of Pediatric Complex Regional Pain Syndrome with Low-Dose Naltrexone. Pain Medicine Case Reports. 2021;5:109-113. Mechanism and preclinical literature 8. Younger J, Parkitny L, McLain D. The use of low-dose naltrexone as a novel anti-inflammatory treatment for chronic pain. Clinical Rheumatology. 2014;33(4):451-459. doi:10.1007/s10067-014-2517-2. 9. Toljan K, Vrooman B. Low-Dose Naltrexone (LDN)-Review of Therapeutic Utilization. Medical Sciences. 2018;6(4):82. doi:10.3390/medsci6040082. 10. Hutchinson MR, Zhang Y, Brown K, et al. Non-stereoselective reversal of neuropathic pain by naloxone and naltrexone: involvement of Toll-like receptor 4. European Journal of Neuroscience. 2008;28(1):20-29. doi:10.1111/j.1460-9568.2008.06321.x. 11. de Oliveira CL, Medeiros LF, de Souza VS, et al. Low-dose naltrexone reverses facial mechanical allodynia in a rat model of trigeminal neuralgia. Neuroscience Letters. 2020;736:135248. doi:10.1016/j.neulet.2020.135248. 12. Naderi Y, Soti M, Soltani M, et al. Co-administration of low-dose naltrexone and carbamazepine remarkably ameliorates allodynia and cognitive deficit in a rat model of trigeminal neuralgia. Scientific Reports. 2025;15:31335. [link] Systematic and narrative reviews 13. Kim PS, Fishman MA. Low-Dose Naltrexone for Chronic Pain: Update and Systematic Review. Current Pain and Headache Reports. 2020;24:64. 14. Soin A, et al. Low-Dose Naltrexone Use for Patients with Chronic Regional Pain Syndrome: A Systematic Literature Review. Pain Physician. 2021;24:E125-E143. PMID: 34213865. [link] 15. Rupp A, Young E, Chadwick AL. Low-dose naltrexone’s utility for non-cancer centralized pain conditions: A scoping review. Pain Medicine. 2023;24(11):1270-1281. 16. The use of naltrexone in the treatment of chronic pain: A systematic review. 2024. [link] 17. Low-Dose Naltrexone: What is the Evidence? A Narrative Review. 2026. [link] CRPS and neuralgia standards 18. Harden RN, McCabe CS, Goebel A, et al. Complex Regional Pain Syndrome: Practical Diagnostic and Treatment Guidelines, 5th Edition. Pain Medicine. 2022;23(Suppl 1):S1-S53. doi:10.1093/pm/pnac046. [link] 19. Bendtsen L, Zakrzewska JM, Abbott J, et al. Trigeminal neuralgia: a practical guide. Practical Neurology. 2021;21:392-402. [link] 20. Guidelines for the management of trigeminal neuralgia. Cleveland Clinic Journal of Medicine. 2023;90(6):355-362. [link] 21. Nalamachu S, Morley-Forster P. Diagnosing and Managing Postherpetic Neuralgia. Drugs & Aging. 2012;29(11):863-869. 22. Johnson RW, Rice ASC. Postherpetic neuralgia. New England Journal of Medicine. 2014;371:1526-1533. Registered studies 23. ClinicalTrials.gov. Low-Dose Naltrexone for the Treatment of Complex Regional Pain Syndrome. Identifier NCT02502162. Stanford; randomized LDN versus placebo; no posted efficacy results at present. [link] 24. ClinicalTrials.gov. Low Dose Naltrexone Therapy for Complex Regional Pain Syndrome. Identifier NCT06306157. Hospital for Special Surgery feasibility study of LDN plus standard care versus placebo plus standard care. [link] 25. ClinicalTrials.gov. Low-Dose Naltrexone for the Treatment of Painful Diabetic Neuropathy. Identifier NCT04678895. Randomized, double-blind, placebo-controlled crossover design. [link] Safety and regulatory sources 26. DailyMed. Naltrexone hydrochloride tablets: prescribing information, contraindications, opioid-free interval, hepatic precautions, and opioid-overdose risk.[link] 27. Substance Abuse and Mental Health Services Administration. Naltrexone: treatment information and opioid-withdrawal/overdose precautions.[link] 28. FDA Orphan Drug Designations. Naltrexone for post-herpetic neuralgia: orphan designation only; this is not FDA approval for PHN treatment.[link] Requested organization sources 29. LDN Research Trust. Efficacy and safety of low-dose naltrexone in painful diabetic neuropathy—summary of the Srinivasan et al. randomized crossover trial.[link] 30. LDN Research Trust. Chronic Pain conference material, including clinician discussion of CRPS, trigeminal neuralgia, and PHN.[link] 31. Kim YH. Low-Dose Naltrexone in Complex Regional Pain Syndrome: Mechanisms, Clinical Evidence, and Individualized Dosing. IFM Synergy. 2026. [link] 32. Kim YH. Low-Dose Naltrexone: Mechanisms, Individualized Dosing, and Clinical Applications in Integrative Medicine. IFM Synergy. 2026. [link] 33. Kim YH. LDN and Neuropathy: The Potential Role of Low-Dose Naltrexone for Treating Neuropathy. www.directintegrativecare.com. 2025. [link] 34. Kim YH. Low-dose naltrexone therapy: Powerful 2026 Benefits. www.directintegrativecare.com. 2026. [link] 35. Kim YH. Pediatric Dosing of LDN Low Dose Naltrexone. YoonHangKim.com. 2025. [link] Note on source weight: Educational materials from LDN Research Trust and the clinical websites above are useful but should not be weighed equivalently to controlled trials, guidelines, or regulatory sources. The strongest direct LDN evidence in this topic remains the single randomized painful diabetic neuropathy trial [1]; CRPS evidence is largely case-based, trigeminal neuralgia evidence is mainly preclinical or post-traumatic neuropathy data, and PHN-specific evidence remains insufficient. Yoon Hang Kim, MD, MPH is the author of MCAS: Epidemic in Plain Sight and LDN Primer, both available on Amazon, and the founder of the LDN Support Group. Professional: www.yoonhangkim.com | Clinical: www.directintegrativecare.com

Yoon Hang Kim, MD, MPH Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician About Dr. Kim Dr. Yoon Hang Kim is a board-certified physician with over 20 years of experience in integrative and functional medicine. He completed fellowship training at the University of Arizona under Dr. Andrew Weil and holds certifications in Preventive Medicine, Medical Acupuncture, and Integrative & Holistic Medicine. He specializes in LDN, autoimmune disease, chronic pain, integrative oncology, fibromyalgia, chronic fatigue syndrome, MCAS, and mold toxicity. He has authored more than 25 peer-reviewed articles and 8 books. Professional: www.yoonhangkim.com | Clinical: www.directintegrativecare.com Important: This article is for educational purposes only and does not constitute medical advice. Always work with a qualified clinician before starting, stopping, or changing any treatment. For detailed dosing guidance and clinical evidence, visit ifmsynergy.com. If you or someone you know is experiencing suicidal thoughts, please contact the 988 Suicide & Crisis Lifeline by calling or texting 988. When "Low Dose" Is Still Too Much: LDN for Complex, Sensitive Clients Why Some Clients Can't Tolerate LDN You've probably heard the phrase "start low, go slow" when it comes to low-dose naltrexone. That's good advice for most people. But what about the client who starts at the lowest recommended dose — and still crashes? It happens more often than you'd think. And when it does, it doesn't mean LDN is the wrong choice. It usually means the dose was still too high. What LDN Is and Why It Helps LDN stands for low-dose naltrexone. At very small doses — usually between 1.5 and 4.5 mg — it works by briefly blocking the body's opioid receptors. Your body notices the block and responds by making more of its own natural painkillers, called endorphins. When those endorphins come back online, many clients feel less pain, less inflammation, and stronger immune function. "The endorphin system is not merely a feel-good mechanism. It is an immune modulator." — ifmsynergy.com When LDN works the way it should, it doesn't just ease pain. It helps reset the whole immune system. That's a big deal for anyone dealing with MCAS, long COVID, autoimmune disease, or chronic fatigue. The Endorphin Crash: What Goes Wrong Here's where it gets tricky. LDN works by temporarily blocking your opioid receptors. The goal is for your body to bounce back by making more endorphins. But some clients — especially those dealing with years of trauma, chronic illness, or nervous system overload — are already running on empty. Their bodies are using every last bit of endorphin just to get through the day. When those clients take even a tiny dose of LDN, the temporary block can push an already stretched system over the edge. That's an endorphin crash. It can look like: • Crushing fatigue that won't lift • Loss of motivation or pleasure • Feeling emotionally numb or flat • In severe cases, thoughts of self-harm This isn't a common reaction. But it's real, and clinicians need to watch for it — especially in clients with post-COVID POTS, MCAS, or a history of serious trauma. When Hormones Make Everything Worse There's another layer that often gets missed: hormones. Estrogen makes mast cells more reactive. When mast cells overfire, they can flood the brain with histamine — causing symptoms like hypervigilance, insomnia, brain fog, and emotional crashes. Meanwhile, histamine tells the body to make even more estrogen. It becomes a vicious loop. Progesterone does the opposite — it tends to calm mast cells down. This means certain times of the month can be the worst times to raise an LDN dose. Around ovulation and just before a period, a sensitive client's mast cells may already be running hot. Adding an LDN increase on top of that hormonal surge can push the system past its limit. The Solution: Think Micrograms, Not Milligrams For clients who have crashed on standard starting doses, the answer is to go much smaller than most clinicians think possible. Instead of starting at 0.5 mg or even 0.1 mg, some clients need to begin at 1 microgram — that's one-thousandth of a milligram. You can prepare this at home: dissolve a 0.1 mg capsule (from a compounding pharmacy) in 100 mL of distilled water using a brown glass bottle. Each 1 mL of that solution contains 1 microgram of LDN. Simple, inexpensive, and incredibly precise. Important: Always confirm your preparation method and starting dose with your prescribing clinician before your first dose. The speed of titration matters just as much. If a client crashed increasing every two weeks, slow it to once a month. If once a month was too fast, try every two months. The body will always tell you what it can handle. Your job is to listen. Whatever schedule failed before — double the timeline. When MCAS Lives in the Brain Most people think of MCAS as a skin-and-gut problem — hives, food reactions, stomach pain. But mast cells live in the brain too. When they overfire in the central nervous system, the symptoms look completely different: • Extreme sensitivity to light, sound, or touch • Feeling "wired but exhausted" • Wild emotional swings • Overreacting to things that shouldn't be a big deal — like a gentle therapy session or a mild workout One of my clients couldn't tolerate neurofeedback — a very low-stimulation therapy — because it triggered a full nervous system shutdown. That's brain-based MCAS in action. Antihistamines that cross into the brain (like Benadryl) can help with this pattern. And once LDN has had a chance to calm things down, a medication called ketotifen can be added. Ketotifen is a direct mast cell stabilizer that reaches the brain — something most other mast cell treatments can't do. Supporting the System While You Titrate For clients working through ultra-low-dose LDN, a few gentle supports can make the road smoother: • Mucuna pruriens — a natural source of L-dopa, which supports dopamine (the brain chemical behind motivation and pleasure). Evidence for dopamine support outside of Parkinson's disease is still limited, but clinical experience has been encouraging in depleted clients. • Saffron — research shows it supports both serotonin and dopamine, and may be comparable to antidepressants in mild-to-moderate cases. European-sourced products tend to have more reliable quality control. • Adrenal adaptogens — like ashwagandha or rhodiola, to support the stress response during the titration process. One critical rule: introduce one thing at a time. In sensitive clients, starting multiple new supplements at once makes it impossible to know what's helping and what's causing a problem. Redefining What "Getting Better" Looks Like In chronic illness, we tend to think of success as "no more symptoms." That's usually unrealistic — and it's damaging to clients who are making real progress they can't see. A better goal is burden reduction. What would your life look like with 25% less fatigue? With 50% less pain? With fewer crashes each month? Each small intervention that helps — even a little — stacks on top of the last one. LDN at microgram doses. Hormone modulation. Mast cell stabilization. Nervous system support. None of these is a cure on its own. But together, they can shift someone from barely surviving to actually living. That's worth the patience it takes to get the dosing right. I walk through specific dosing timelines and clinical protocols on ifmsynergy.com — that's the best place to dig deeper. Selected References Dulal D, Maraey A, Elsharnoby H, et al. Impact of COVID-19 pandemic on the incidence and prevalence of postural orthostatic tachycardia syndrome. Eur Heart J Qual Care Clin Outcomes. 2025;11(5):698-704. Hausenblas HA, Saha D, Dubyak PJ, Anton SD. Saffron and major depressive disorder: a meta-analysis of randomized clinical trials. J Integr Med. 2013;11(6):377-383. Zagon IS, McLaughlin PJ. Naltrexone modulates tumor response in mice with neuroblastoma. Science. 1983;221(4611):671-673. About the Author Yoon Hang Kim, MD, MPH is the author of MCAS: Epidemic in Plain Sight and LDN Primer, both available on Amazon. He is the founder of the LDN Support Group. Professional: www.yoonhangkim.com | Clinical: www.directintegrativecare.com

INTEGRATIVE INFECTIOUS DISEASE Yoon Hang Kim, MD, MPH Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician Dr. Yoon Hang Kim is board-certified in Preventive Medicine and practices integrative & functional medicine. He completed the University of Arizona Center for Integrative Medicine Osher Fellowship under Dr. Andrew Weil and holds certifications in preventive medicine, medical acupuncture, and integrative and functional medicine. He is an IFM Scholar with over 20 years of clinical experience. Dr. Kim specializes in low dose naltrexone (LDN), autoimmune conditions, chronic pain, integrative oncology, fibromyalgia, chronic fatigue syndrome, mast cell activation syndrome, and mold toxicity. He is the author of 8 books — including MCAS: Epidemic in Plain Sight and LDN Primer — and has published more than 25 peer-reviewed articles. He is the founder of the LDN Support Group. Professional: www.yoonhangkim.com | Clinical: www.directintegrativecare.com Important: This article is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Lyme disease and tick-borne co-infections require individualized evaluation by qualified clinicians. Herbal protocols should be undertaken under clinical supervision. If you experience signs of a severe Jarisch-Herxheimer reaction, anaphylaxis, or neurological deterioration, seek emergency medical care immediately. Always consult your own physician before making changes to your treatment plan. The Cowden+ Support Program: A Comprehensive Guide to Herbal-Based Lyme Disease Management Summary Table Element Detail What it is A structured, 6-month rotational herbal and botanical regimen for chronic Lyme disease and co-infections Developer Lee Cowden, MD; now marketed by Nutramedix as the Cowden+ Support Program Core strategy Monthly rotation of three proprietary herbal blends (Nutra-BRL → Nutra-BRT → Nutra-BBS+) with biofilm-disrupting enzymes and detoxification support Duration 6 months initial; Months 4–6 repeatable as needed Strongest evidence Component-level and in vitro: University of New Haven and Johns Hopkins studies show Samento, Banderol, and Artemisia annua active against B. burgdorferi morphological forms [5][8]; Stevia evidence is discordant across labs Evidence limitations No prospective randomized trials of the complete protocol in humans; clinical data is observational and practitioner-reported Key safety concern Distinct transporter/enzyme effects: Banderol inhibits hepatic uptake transporters OATP1B1/OATP1B3; Samento activates PXR and induces ABCB1/P-glycoprotein and CYP3A4 effects. Clinical magnitude unestablished — reconcile medications [9] Approximate cost USD $250–$350/month; $1,500–$2,100 for full 6-month program Best candidates Clients with antibiotic failure, antibiotic intolerance, seronegative Lyme-like syndrome, or significant co-infections What Is the Cowden+ Support Program? The Cowden Support Program, now marketed as the Cowden+ Support Program by Nutramedix, is a structured, six-month herbal and botanical regimen designed to support clients with chronic Lyme disease, co-infections, and related complex chronic illnesses. Developed by Lee Cowden, MD, the protocol employs a rotational approach using proprietary herbal blends, biofilm-support enzymes, and detoxification support to address microbial challenges, inflammatory responses, and Herxheimer-like reaction management [1]. This document provides an overview of the protocol's components, clinical rationale, practical implementation, and evidence base for healthcare providers and informed clients. How Did the Cowden Protocol Develop? The Cowden Protocol emerged from clinical experience treating clients with documented or suspected Borrelia burgdorferi (Lyme) infections who either declined antibiotic therapy, experienced antibiotic resistance or intolerance, or had persistent symptoms after conventional treatment [1]. Dr. Lee Cowden and collaborators described observational data from a 2003 Dallas cohort reporting symptomatic improvement in Lyme clients treated with the herbal support approach [1]. The protocol gained adoption among integrative and functional medicine practitioners, particularly those treating Lyme-complex cases empirically — that is, clinical presentations consistent with Lyme even when serology is negative or indeterminate. The program was recently revised and rebranded as Cowden+ Support Program, featuring streamlined dosing (twice-daily rather than multiple daily doses), enhanced proprietary blended formulas to simplify adherence, and updated supporting materials [2]. Despite updates in packaging and delivery, the core mechanistic approach remains consistent. A note on evidence level: The 2003 Dallas cohort is not available as a peer-reviewed primary publication, and this article does not present it as a formal study. The most traceable clinical observation comes from Richard Horowitz, MD, a founding ILADS member, who presented his experience using the Cowden Support Program in a group of Lyme and co-infection clients at the 2007 ILADS Annual Conference and later described it in his 2013 book Why Can't I Get Better? He reported that roughly two-thirds to three-quarters of clients improved on full or modified Cowden strategies (used with or without antibiotics), and he observed relapse when the protocol was used for less than six months. Critically, Horowitz himself concluded that controlled trials were needed to determine which herbal combinations are safest and most effective. This is uncontrolled clinical observation, not randomized trial data, and insufficient methodological detail is available to estimate a treatment effect reliably. A separate nine-month observational evaluation was later conducted in Augsburg, Germany. Both represent practitioner and observational experience. Why a Functional-Medicine Model Fits Better Than "Bug in a Biofilm" Before detailing the protocol, it helps to frame why an integrative, multi-targeted botanical strategy is philosophically coherent — and here the functional-medicine model has grown considerably more sophisticated than a simple "persistent hidden infection" narrative. Emerging biology supports a host-response model of persistent post-Lyme symptoms rather than attributing everything to viable organisms hiding in biofilm. In treated Lyme neuroborreliosis, persistent symptoms have been associated with sustained systemic interferon-α even after cerebrospinal-fluid inflammation resolved [15]. Metabolomic work has identified differences in glycerophospholipids, bile acids, and acylcarnitines between clients with post-treatment Lyme disease symptoms and recovered controls [16]. This fits Richard Horowitz's Multiple Systemic Infectious Disease Syndrome (MSIDS) framework, which treats persistent illness as multifactorial — infection, immune dysregulation, inflammation, gastrointestinal factors, environmental exposures, nutritional abnormalities, sleep, autonomic and mitochondrial dysfunction, and other contributors — rather than reducing it to a single cause [22]. Notably, even the 2025 National Academies report on Lyme infection-associated chronic illnesses has moved toward this broader model, explicitly weighing pathogen/antigen persistence, autoimmunity, immune dysregulation, and microbiome alterations rather than treating the biology as settled [17]. The clinical takeaway: a strategy that simultaneously applies botanical antimicrobial pressure and addresses host resilience, inflammation, detoxification capacity, and coexisting conditions is conceptually aligned with where the science is actually heading — a model in which persistent viable infection is one possible mechanism among several, not the only permissible explanation. Where the Cowden Protocol Sits Relative to ILADS The 2014 ILADS guideline is philosophically relevant to this protocol, though it is important to be precise: ILADS emphasizes individualized assessment, clinical judgment, reassessment of the original diagnosis, evaluation for coinfections and alternative causes of persistent symptoms, patient preferences, and individualized therapeutic trials rather than a rigid one-size-fits-all approach [18]. ILADS does not specifically endorse or validate the Cowden herbal protocol — its persistent-disease recommendations primarily address antibiotic retreatment, and ILADS grades much of that evidence as low quality. The accurate framing is therefore that the Cowden Protocol is compatible with the individualized, shared-decision-making philosophy used by many ILADS-oriented clinicians, not that it is "supported by ILADS." What Is the Core Philosophy and Mechanism? The Cowden Protocol operates on several integrated principles: Rotational Antimicrobial Targeting Rather than a single antimicrobial agent, the protocol rotates through three distinct herbal blends over a six-month cycle, each with slightly different microbial targets. On the working hypothesis (plausible but not established specifically for the Cowden Protocol), this approach aims to: Reduce adaptive resistance by the target organisms Address polymicrobial communities (Lyme commonly co-exists with Babesia, Ehrlichia, Bartonella, and others) Minimize Herxheimer reactions by pulsing rather than sustaining single-agent therapy Improve long-term tolerability through chemical diversity Biofilm Disruption Proteolytic enzymes (bromelain and serrapeptase) are incorporated on the hypothesis that degradation of fibrinous or proteinaceous extracellular matrices may improve antimicrobial access to organisms sheltered within biofilm. Sapi et al. (2012) demonstrated that Borrelia burgdorferi can form organized aggregates with extracellular polymeric matrix characteristics consistent with biofilm in vitro [3], which is genuine mechanistic evidence that the target exists. Bromelain also has human anti-inflammatory and pharmacologic literature [19], and bromelain-based enzymatic debridement has shown effects on biofilm-containing chronic wounds in human studies [20]. However, this is mechanistically plausible extrapolation, not established fact: no human study has demonstrated that orally administered bromelain or serrapeptase disrupts Borrelia biofilm in vivo. The rationale is retained here as a working hypothesis, correctly leveled. Drainage Support and Flare Tolerability The protocol incorporates drainage-supporting botanicals (burbur-pinella, dandelion) intended to support elimination pathways during treatment-associated symptom flares. This use derives primarily from traditional and clinical practice rather than controlled studies demonstrating accelerated toxin clearance or prevention of Jarisch-Herxheimer reactions. The staged, "go-low-and-slow" design is central to the protocol's tolerability philosophy, on the clinical reasoning that rapid microbial die-off without supportive drainage may provoke treatment-limiting flares. Nutritional and Energetic Support Magnesium malate is included for muscle pain, fatigue, and ATP production support — addressing a common Lyme symptom cluster. This reflects understanding that chronic Lyme is not purely an antimicrobial challenge but a multi-system inflammatory and energetic dysfunction [14]. What Does the Six-Month Program Look Like? Month 1: Embarking on Microbial Support Dosing Philosophy: Low starting dose, gradual titration upward over 2–4 weeks to minimize Herxheimer reactions in newly treated clients. Primary Products: Nutra-BRL (contains Stevia, Samento [Cat's Claw TOA-free], and Banderol): Broad-spectrum microbial and inflammatory support Takuna: Traditional Amazonian plant used historically for inflammation and immune modulation Bromelain and Serrapeptase: Proteolytic enzymes targeting biofilm matrix Burbur-Pinella: Herbal drainage/support formula; practitioner-directed, particularly during treatment-associated symptom flares Dandelion (root/leaf extract): Liver and lymph drainage; diuretic properties support elimination pathways Magnesium Malate: 2:1 complex (magnesium and malic acid) for muscle pain, mitochondrial support, and fatigue Clinical Goal: Establish tolerability and baseline, begin gentle microbial pressure, support elimination pathways. Month 2: Rotation to New Antimicrobial Blend Dosing Philosophy: Reset to low dose again despite prior month's tolerance, as this introduces a new herbal combination with different target organisms. Primary Products: Nutra-BRT (contains Cumanda and Houttuynia): Different botanical targets than Nutra-BRL; Houttuynia is a traditional antimicrobial from East Asian herbalism GlucoMedix (contains Stevia and Samento): Provides continued Samento exposure at lower concentration alongside new blend Takuna, Bromelain, Serrapeptase, Burbur-Pinella, Dandelion, Magnesium Malate: Continued support as in Month 1 Clinical Goal: Introduce new microbial pressure vector; monitor for different Herxheimer profile. Month 3: Introduction of Botanical Combination Dosing Philosophy: Low start with new blend; this month introduces the most complex herbal formula in the 6-month cycle. Primary Products: Nutra-BBS+ (contains Elecampane, Jalap, Artemisia annua, and Capirona): Traditional anti-parasitic and antimicrobial herbs; Artemisia annua (sweet wormwood) has documented in vitro activity against various pathogens including B. burgdorferi stationary phase forms [8] GlucoMedix: Continued as in Month 2 Takuna, Bromelain, Serrapeptase, Burbur-Pinella, Dandelion, Magnesium Malate: Continued support Clinical Goal: Introduce botanicals with anti-parasitic profile; support for Babesia and other co-infections. Recommendation is to continue 2 months past subjective "feeling well" to address persistent organisms. Months 4, 5, 6: Intensified Dosing with Repeated Blends Dosing Philosophy: Return to Month 1–3 herbal combinations but at higher, established doses to maximize microbial support after baseline has been established. Month 4: Nutra-BRL (full dose) Month 5: Nutra-BRT (full dose) Month 6: Nutra-BBS+ (full dose) Plus supportive products at maintained doses: Bromelain, Serrapeptase, Burbur-Pinella, Dandelion, Magnesium Malate. Clinical Goal: Consolidate gains from Months 1–3 with higher-intensity therapy; repeat Months 4–6 as needed until symptom stabilization achieved. What Are the Key Active Herbal Components? Samento (Cat's Claw, Uncaria tomentosa) Traditional use: Immune support, anti-inflammatory, antimicrobial (Peruvian traditional medicine) Botanical mechanism: Pentacyclic oxindole alkaloids (TOAs reduced in Samento formulation) may modulate NF-κB signaling and support immune regulation [4] Applied use in protocol: Broad-spectrum microbial activity including against spirochetes; used in both Nutra-BRL and GlucoMedix formulas In vitro evidence: In the Datar/Sapi (2010) Townsend Letter work, Samento was active against all B. burgdorferi morphological forms — spirochetes, round bodies, and biofilm-like colonies — outperforming doxycycline against non-spirochetal forms, especially combined with Banderol [5]. Separately, the Feng/Zhang (2020) Johns Hopkins screen found Uncaria tomentosa active against stationary-phase B. burgdorferi — independent support for this botanical, though that study tested the herb, not the Cowden product or protocol [8]. Safety data: Weiss (2019) found Samento weakly inhibits CYP3A4 (~40% at 1%) and, via PXR activation, induces ABCB1/P-glycoprotein and related genes — an induction profile, not simple inhibition. This differs entirely from Banderol's profile (OATP1B1/1B3 inhibition). Reconcile medications; clinical magnitude at human doses is unestablished [9]. Clinical note: Some practitioners titrate carefully due to immune-stimulating potential; clients with autoimmune conditions may require monitoring. Banderol (Otoba parvifolia) Traditional use: Amazonian antimicrobial; traditional use for infections Botanical mechanism: Benzofuran and phenolic compounds with antimicrobial activity Applied use in protocol: Often selected for spirochete and co-infection coverage; combined with Samento for synergy In vitro evidence: More effective in combination with Samento than either agent alone against all three B. burgdorferi morphological forms [5]. Pharmacokinetic interaction profile characterized by Weiss (2019) [9]. Clinical note: Less studied than Samento in peer-reviewed literature; inclusion reflects practitioner experience and traditional Amazonian ethnobotany. Cumanda (Himatanthus sucuuba) Traditional use: South American rainforest plant used for various infections Botanical mechanism: Understudied in Western literature; traditional use suggests anti-inflammatory and antimicrobial properties Applied use in protocol: Represents new microbial target in Month 2 rotation Clinical note: Limited peer-reviewed data; inclusion is empirical based on clinical experience. Sapi's expanded in vitro evaluations (presented at national Lyme conferences 2013 and 2015) tested Cumanda among other Cowden Protocol herbs against three forms of B. burgdorferi [6]. Houttuynia (Houttuynia cordata) Traditional use: East Asian ethnomedicine (Japan, Vietnam, China); used for respiratory and urinary tract infections Botanical mechanism: Volatile oils and polyphenols with demonstrated antimicrobial activity against various bacteria and viruses [10] Applied use in protocol: Provides different microbial pressure than Samento/Banderol; often selected for persistent respiratory or CNS-related Lyme symptoms Clinical note: Some in vitro data supporting antimicrobial activity; clinical translation to Lyme disease is primarily practitioner-based. Artemisia annua (Sweet Wormwood) Traditional use: Traditional Chinese medicine for febrile illnesses; artemisinin derivatives are established antimalarial agents Botanical mechanism: Artemisinin and sesquiterpene lactones; well-documented antimicrobial and antiparasitic activity Applied use in protocol: Specifically included for parasitic co-infections (particularly Babesia), reflecting mechanism-based rationale In vitro evidence: Ranked among the seven most active botanical agents against stationary phase B. burgdorferi in the Feng et al. (2020) Johns Hopkins study [8]. Artemisinin derivatives have an established clinical track record as antimalarials. Clinical note: Inclusion in Month 3 supports antiparasitic intentions, particularly for Babesia co-infection. Stevia (Stevia rebaudiana) Applied use in protocol: Included in Nutra-BRL and GlucoMedix blends; often highlighted for anti-biofilm activity. In vitro evidence — and an important caveat: The laboratory evidence for Stevia is discordant, and this is a useful pharmacognosy teaching point. Theophilus et al. (2015) reported that a particular whole-leaf Stevia extract had significant activity against multiple B. burgdorferi morphological forms, including biofilm [7]. However, the later Feng et al. (2020) Johns Hopkins botanical screen did not reproduce comparably impressive activity for Stevia under its stationary-phase assay conditions [8]. Differences in extraction method, preparation, concentration, organism state, and assay design likely account for the discordance. The clinical lesson: "Stevia" is not a chemically uniform intervention. Different extracts cannot be treated as interchangeable, and product formulation, dose, and preparation matter — a point emphasized in the 2023 comprehensive review of herbal supplements used for persistent Lyme symptoms [21]. Bromelain (Pineapple Enzyme) Mechanism: Serine protease; degrades fibrin and extracellular matrix proteins Applied use: Biofilm-disruption support; anti-inflammatory properties via suppression of cytokine release Evidence base: Rationale supported by Sapi et al. (2012) confirmation of true B. burgdorferi biofilm formation [3]. Direct clinical evidence for bromelain-mediated biofilm disruption in Lyme specifically remains preclinical. Serrapeptase (Serratia peptidase) Mechanism: Serine protease from Serratia marcescens; cleaves non-collagen proteins Applied use: Similar to bromelain — biofilm matrix degradation and inflammatory modulation Evidence base: Laboratory evidence for biofilm disruption; less extensive clinical trial data than bromelain, but combined use is common in integrative practice. Burbur-Pinella Composition: Proprietary blend (exact constituents vary by manufacturer) traditionally combining Burbur (Desmodium species) and Pinella Mechanism: Used within the Cowden system as a practitioner-directed drainage/support formula. Note: this is not a "binder" in the physicochemical sense — activated charcoal and certain clays adsorb and bind toxins, whereas an herbal drainage tincture is conceptually different and lacks adsorption/binding data Applied use: Positioned for use during treatment-associated symptom flares; often described as "rescue" dosing when reactions intensify Clinical note: Central to the protocol's tolerability philosophy, but its use derives from traditional and clinical practice rather than controlled studies demonstrating accelerated toxin clearance or prevention of Jarisch-Herxheimer reactions. Dandelion (Taraxacum officinale) Mechanism: Diuretic; bitter compound stimulation of bile; mineral-rich (potassium, calcium) Applied use: Hepatic and renal clearance support; addresses mineral depletion from chronic illness and increased elimination demands Evidence base: Long traditional use with limited high-quality clinical trials; supportive evidence for hepatic function and mineral status [11]. Magnesium Malate (Mg-Malate Complex) Mechanism: Magnesium is a cofactor in >300 enzymatic reactions; malic acid is involved in the Krebs cycle; combination supports mitochondrial ATP production Applied use: Specifically targets Lyme-associated muscle pain, fatigue, and energetic dysfunction Evidence base: Magnesium deficiency is common in chronic illness states; the malate form has evidence supporting its use in fibromyalgia-spectrum pain conditions [14]. The combined inclusion rationale is physiologically sound. What Are the Clinical Implementation Considerations? Client Selection and Screening The Cowden Protocol is typically offered to clients with: Documented Lyme disease (positive 2-tier serology) with persistent symptoms despite antibiotics Seronegative Lyme-like syndrome (clinical Lyme presentation without seroconversion) Lyme with significant co-infections (Babesia, Bartonella, Ehrlichia) Inability or unwillingness to tolerate conventional antibiotic therapy (allergy, GI intolerance, or prior adverse response) Previous antibiotic therapy with inadequate response Cautions and contraindications: Significant hepatic dysfunction (high herbal load); requires case-by-case evaluation Severe immunocompromise (may require modified dosing; some practitioners advise caution with immune-stimulating herbs like Samento) Concurrent antibiotic or antimicrobial therapy: often combined intentionally, but requires coordinated monitoring. Weiss (2019) found distinct in vitro transporter/enzyme effects — Banderol inhibits hepatic uptake transporters OATP1B1/OATP1B3, while Samento activates PXR and induces ABCB1/P-glycoprotein along with CYP3A4 effects; reconcile medications, especially those with narrow therapeutic indices or transporter-dependent disposition [9] Pregnancy and lactation: human reproductive-safety data for these multi-herbal formulations are inadequate. Pregnancy and lactation require separate, ingredient-by-ingredient risk assessment; the complete Cowden Protocol has not been adequately studied in this population Treatment-Emergent Flares: Not Always "Die-Off" Treatment-emergent flaring is commonly reported clinically with the Cowden Protocol, and slow titration is a reasonable tolerability strategy. However, an important caution: Cowden-specific prospective data establishing the incidence, onset, duration, severity, or predictive value of these reactions do not exist. This section should be read as clinical-practice guidance, not as a prospectively validated trajectory. More importantly, a symptom flare should not automatically be interpreted as microbial die-off. The differential is broad and clinically consequential: Direct botanical intolerance Mast-cell / histamine activation (particularly important in MCAS-prone clients) Drug or herb-drug interaction Gastrointestinal intolerance Hepatic adverse effect Allergy Underlying disease fluctuation Unrelated intercurrent illness Reflexively labeling every flare a "Herxheimer reaction" risks missing an adverse drug effect, an allergy, or a mast-cell event that warrants a different response. This distinction matters especially in clients with known or suspected mast cell activation syndrome, in whom botanical exposures can provoke mediator release that mimics — but is mechanistically distinct from — a die-off reaction. Tolerability strategies commonly used: Low initial dosing with slow titration Reset to low dose when introducing new blends Concurrent drainage-support botanicals from the outset Client education on the reaction spectrum and, critically, on the difference between a tolerability flare and a true adverse reaction that requires stopping When a flare occurs: Reassess the differential above before assuming die-off Reduce antimicrobial product doses temporarily Supportive care (rest, hydration, sleep) Increase drainage-support botanicals as practitioner-directed (traditional/clinical rationale, not proven to prevent Jarisch-Herxheimer reactions) Discontinue and reassess if the reaction is severe, allergic, or suggests hepatic injury How Does the Cowden Protocol Integrate with Other Therapies? With Antibiotics Some clinicians use the Cowden Protocol concurrently with antibiotics during specific phases, reasoning that multi-targeted therapy may improve outcomes. This is individualized and requires close monitoring. The protocol was originally designed as an alternative to antibiotics, but combination use is increasingly discussed in integrated practice. Sapi et al. (2011) demonstrated that different antibiotics have variable effectiveness against different morphological forms of B. burgdorferi — doxycycline was effective against spirochetes but not against round bodies or biofilm colonies — providing mechanistic rationale for combination approaches [6]. With LDN (Low-Dose Naltrexone) LDN is used off-label in Lyme to reduce inflammation and modulate immune response. Many practitioners combine LDN (titrated separately) with the Cowden Protocol, though no formal evidence exists on drug-herb interactions. The combination is generally regarded as synergistic for anti-inflammatory effect but requires coordination of timing and monitoring. For more on LDN, see the LDN Primer and the LDN articles on ifmsynergy.com. With Other Supplements Practitioners often layer in: Probiotics and prebiotic fiber: Support microbiome restoration post-die-off Omega-3 fatty acids: Anti-inflammatory support Curcumin/turmeric: Additional anti-inflammatory and antimicrobial activity High-dose vitamin C: Immune support and collagen synthesis CoQ10 or mitochondrial support formulas: Additional energy support Binders (activated charcoal, bentonite clay, humic/fulvic acids): Enhanced toxin elimination during flares No formal protocols exist for these combinations; clinicians titrate based on tolerance and symptom response. How Should Response Be Monitored? Baseline assessment: Detailed symptom inventory (pain, fatigue, cognitive function, emotional affect, infections/fevers, GI function, sleep) Lab assessment if available (CBC, CMP, liver enzymes, inflammatory markers if desired; serology if Lyme status unknown) Functional capacity assessment (ability to work, exercise, self-care) Ongoing monitoring (typically at 2–4 week intervals): Symptom tracking using same inventory Flare pattern and intensity (with the differential in mind — not every flare is die-off) Tolerability of current dosing Functional improvement or decline Adverse events or new symptoms Typical response pattern (from clinical observation, not prospective data — hold loosely, and individualize): Early weeks: Treatment-emergent flares are commonly reported as dosing begins; remember these are not automatically die-off (see the flare differential above) First few months: Gradual symptom improvement is often described, with energy and sleep frequently improving first Months 3–6: More substantial improvement in fatigue, pain, cognitive function, and infection frequency in those who respond Beyond 6 months: Continued slow improvement in responders; the protocol may be repeated (Months 4–6 cycle) or extended for maintenance These timeframes come from practitioner experience, not controlled trials, and vary widely between individuals. Lack of response: If no improvement or worsening after 3 months despite optimal dosing and careful flare management, the protocol may be modified, discontinued, or supplemented with different approaches — other herbal regimens such as the Buhner or Zhang protocols, introduction of antibiotics, or investigation of other causes of symptoms. What Does the Evidence Actually Show? Published Evidence In vitro studies (strongest evidence tier for this protocol): Datar/Sapi (2010) demonstrated that Samento and Banderol, the two primary herbal extracts in the Cowden Protocol, had significant effects on all morphological forms of B. burgdorferi — spirochetes, round bodies, and biofilm-like colonies — especially in combination, while doxycycline was effective only against spirochetes [5]. This is directly relevant Cowden-component work, but it was published in the Townsend Letter (a practitioner journal), not as a peer-reviewed human clinical study. Feng/Zhang (2020), a separate Johns Hopkins–affiliated laboratory program, independently strengthens the case for several botanicals used by integrative Lyme clinicians — especially Uncaria tomentosa (Cat's Claw) and Artemisia annua (Sweet Wormwood) — finding 7 of 12 tested botanicals active against stationary-phase B. burgdorferi, with Cryptolepis sanguinolenta uniquely achieving complete eradication in subculture [8]. Important caveat: this study did not test the complete Cowden Protocol as a clinical intervention, and it did not reproduce the impressive Stevia results seen elsewhere. Sapi et al. (2011) showed that standard antibiotics have variable effectiveness against different B. burgdorferi morphological forms — doxycycline active against spirochetes but not biofilm/round bodies — providing mechanistic rationale for multi-targeted approaches [6]. Sapi et al. (2012) characterized B. burgdorferi biofilm formation in vitro, confirming the biofilm target exists [3]. Stevia — discordant evidence: Theophilus et al. (2015) found whole-leaf Stevia active against all B. burgdorferi forms including biofilm [7]; Feng/Zhang (2020) did not reproduce comparable activity under different assay conditions [8]. Extract and preparation differences matter. Thompson et al. (2023) reviewed 18 herbal supplements used for persistent Lyme symptoms, confirming in vitro anti-Borrelia activity for cat's claw and sweet wormwood among others, while emphasizing that human in vivo and clinical trial data are lacking and that product variability, dosing, and drug-interaction/additive-effect risks are real clinical concerns [21]. Goc & Rath (2016) reviewed anti-borreliae phytochemicals and micronutrients, adding mechanistic context [12]. Observational clinical data: The most traceable clinical signal comes from Richard Horowitz, MD, who presented his Cowden Support Program experience at the 2007 ILADS conference and described it further in his 2013 book, reporting improvement in roughly two-thirds to three-quarters of clients on full or modified strategies (with or without antibiotics), and relapse when used for less than six months — while explicitly calling for controlled trials [1]. A separate nine-month observational evaluation was conducted in Augsburg, Germany. Large real-world registry data from MyLymeData (LymeDisease.org) shows marked heterogeneity in treatment response and associations between outcomes, treatment patterns, and Lyme-focused clinicians — but because it is observational and self-selected, it cannot establish causality [23]. All of this is practitioner and observational experience, not controlled-trial evidence. Safety data: Weiss (2019) found that Samento and Banderol have distinct in vitro interaction profiles: Banderol potently inhibits the hepatic uptake transporters OATP1B1 and OATP1B3, while Samento weakly inhibits CYP3A4 (~40% at 1%) and, via PXR activation, induces ABCB1/P-glycoprotein and related genes. Neither straightforwardly inhibits P-glycoprotein. OATP inhibition could theoretically increase systemic exposure of susceptible drug substrates, whereas P-gp induction could decrease exposure to others — so the interaction cannot be reduced to "CYP/P-gp inhibition." The authors emphasized that clinical magnitude at human doses remains uncertain [9]. Limitations of Current Evidence No randomized controlled trials comparing the Cowden Protocol to placebo or antibiotics in Lyme disease No large prospective cohorts with standardized outcome measures Limited pharmacokinetic data on herbal absorption, metabolism, and clearance in Lyme clients Difficulty in blinding (obvious taste and odor of tinctures) High heterogeneity of Lyme presentations and comorbidities The reported improvement figures (roughly two-thirds to three-quarters) come from uncontrolled practitioner observation, not from a published controlled study with defined endpoints Clinical transparency note: These limitations should be discussed openly with clients. The mechanistic plausibility is supported by in vitro research from credible laboratories (University of New Haven, Johns Hopkins), but the gap between in vitro activity and clinical efficacy in human Lyme disease remains unbridged by controlled trials. Conventional infectious-disease reviewers have raised pointed concerns about unvalidated Lyme therapies and about safety, product regulation, and drug interactions [13]; engaging that critique honestly — rather than ignoring it — is part of practicing integrative medicine with intellectual integrity. How Does the Cowden Protocol Compare to Other Herbal Lyme Protocols? Feature Cowden Protocol Buhner Protocol Zhang Protocol Philosophy Rotational antimicrobial cycling with structured schedule Immune support + anti-inflammatory herbs; less structured Traditional Chinese herbal formulas Format Pre-packaged monthly kits (liquid tinctures) Individual herbs (capsules/tinctures) Capsules Duration 6 months (repeatable) 3–6 months (flexible) 6–12 months (individualized) Monthly cost (approx.) USD $250–$350 USD $50–$100 USD $100–$250 Herx potential Higher (larger microbial pressure) Lower (more gradual) Moderate Structure level High (defined rotation schedule) Low (client-driven titration) Moderate (individualized) In vitro evidence for key herbs Yes (Samento, Banderol, Stevia, Artemisia) Yes (some overlapping herbs) Limited Integration with TCM No No Yes (acupuncture, other modalities) Choice among protocols is often based on client preference, practitioner familiarity, cost tolerance, and initial Herx tolerance. What Are the Cost and Practical Considerations? Pricing: Monthly kit (Cowden+ Support Program): Approximately USD $250–$350 per month depending on vendor and geography Full 6-month program: Approximately USD $1,500–$2,100 for initial 6 months Continuation (Months 4–6 repeat): Additional cost if repeating the cycle Individual components: Practitioners and clients may purchase individual products separately for cost flexibility or customization Dosing burden: The original Cowden Protocol required 4–6 doses daily of multiple tinctures, creating substantial adherence challenges. The revised Cowden+ program reduces this to twice-daily dosing but still requires consistent schedule adherence. Access: Available directly from Nutramedix, through integrative practitioners, and from third-party vendors. Authenticity assurance varies among resellers. What Should Healthcare Providers Take Away? Screening and selection: Choose clients with documented or high-likelihood Lyme, seronegative persistence, or antibiotic failure; screen for hepatic function and reconcile concurrent medications (note the distinct transporter/enzyme effects — Banderol OATP1B1/1B3 inhibition; Samento PXR-mediated ABCB1/P-gp induction and CYP3A4 effects [9]) Set expectations: Educate clients that treatment-emergent flares are commonly reported (though not prospectively characterized for this protocol), that the overall course typically spans 6–12 months, and that a flare is not automatically die-off — the differential includes intolerance, allergy, mast-cell activation, and drug interaction Dosing protocol: Start Month 1 low, titrate slowly, reset to low with each new blend (Months 2–3), then increase to full dose (Months 4–6) Flare management: Treat treatment-emergent flares thoughtfully — reassess the differential (intolerance, allergy, mast-cell activation, drug interaction, hepatic/GI effect) before assuming die-off; use drainage support as practitioner-directed; reduce or pause dosing as needed Monitoring: Track symptoms systematically; assess at 2–4 week intervals; adjust based on response and tolerability Integration: Consider concurrent LDN, antibiotics (if appropriate), probiotics, and lifestyle optimization (sleep, stress, gentle exercise) Transparency: Discuss limited RCT evidence honestly; frame as "evidence-informed, clinician experience–supported" rather than "evidence-based" in the strict sense; the in vitro data is credible but clinical trial data is lacking Cost and adherence: Discuss total cost upfront; consider month-by-month sustainability; explore alternative products if needed What Is the Bottom Line? The Cowden Support Program is a structured integrative botanical protocol whose rationale is supported by traditional phytotherapy, laboratory evidence for several constituent botanicals, and limited favorable clinical observations. Its strongest evidence is component-level and preclinical rather than clinical: the complete program has not undergone prospective randomized evaluation, and several commonly cited mechanisms — including systemic biofilm disruption, "detoxification," and predictable Herxheimer trajectories — remain hypotheses derived primarily from laboratory findings and practitioner experience. Within an ILADS-oriented or functional-medicine framework, its principal clinical appeal is the ability to individualize and rotate botanical antimicrobial and anti-inflammatory strategies while simultaneously addressing host resilience, treatment tolerability, coexisting conditions, and noninfectious contributors to persistent symptoms. That last point is where the functional-medicine model has genuinely strengthened: persistent post-Lyme illness increasingly appears to involve immune, inflammatory, metabolic, and autonomic dysregulation — not viable infection alone [15][16][17][22]. A protocol that pairs botanical pressure with attention to the whole host is conceptually aligned with that broader, more accurate picture. Successful implementation requires informed client selection, clear dosing adherence, thoughtful management of treatment-emergent flares (with the full differential in mind, not a reflexive "die-off" label), and honest goal-setting. The protocol is best employed within an integrated framework that addresses not only the infection but also immune resilience, inflammation, detoxification capacity, nutritional status, coexisting conditions such as MCAS, and lifestyle factors. For clinicians and clients navigating chronic Lyme disease, the Cowden Protocol offers a defined, reproducible botanical pathway with growing recognition in functional and integrative medicine — one whose evidence base should be described precisely and honestly, neither dismissed as conventional medicine sometimes does nor oversold as promotional material sometimes does. Important: This article is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Lyme disease and tick-borne co-infections require individualized evaluation by qualified clinicians. Always consult your own physician before making changes to your treatment plan. Frequently Asked Questions Is the Cowden Protocol FDA-approved for treating Lyme disease? No. The Cowden Protocol products are marketed as dietary supplements, not as FDA-approved drugs for treating Lyme disease. The protocol is used off-label by integrative and functional medicine practitioners based on in vitro evidence and clinical experience. This is an important distinction that clients should understand. Can I use the Cowden Protocol instead of antibiotics? This is a clinical decision that should be made with your treating physician. Some clients use the Cowden Protocol as an alternative to antibiotics (particularly when antibiotics have failed or are poorly tolerated), while others use it concurrently with antibiotic therapy. The protocol was originally designed as a non-antibiotic approach, but combination use is increasingly common in integrative practice. How long does it take to see improvement? Practitioners report gradual improvement in energy, sleep, and pain over the first few months, with more substantial functional improvement often described by months 3–6 in those who respond, and some clients needing repeated cycles. These timeframes come from clinical observation, not prospective studies, so they should be held loosely. Treatment-emergent flares are common early on — but a flare is not automatically "die-off." It can reflect botanical intolerance, an allergic or mast-cell reaction, a drug interaction, or a hepatic or GI effect, and those possibilities should be considered rather than assumed away. Are there drug interactions I should know about? Yes — and the picture is more nuanced than a simple "these herbs inhibit drug metabolism." Weiss (2019) found that Samento and Banderol have completely different interaction profiles in vitro [9]. Banderol potently inhibited the hepatic uptake transporters OATP1B1 and OATP1B3, which could theoretically raise blood levels of certain medications. Samento activated the PXR receptor and induced ABCB1/P-glycoprotein (an effect opposite to inhibition, which could theoretically lower levels of some drugs), along with a roughly 40% CYP3A4 inhibition at higher concentrations. The clinical magnitude at usual human doses is unknown. The practical takeaway: give your clinician a complete list of all medications and supplements, with particular attention to drugs that have a narrow therapeutic window or that depend on these transporters, so interactions can be assessed individually. Is there peer-reviewed evidence for the Cowden Protocol? The individual herbal components — particularly Samento, Banderol, Artemisia annua, and Stevia — have been studied in vitro at academic institutions including the University of New Haven and Johns Hopkins Bloomberg School of Public Health [5][6][7][8]. These studies demonstrate antimicrobial activity against B. burgdorferi in laboratory settings. However, no randomized controlled clinical trials have evaluated the complete Cowden Protocol in human Lyme disease clients. The clinical evidence remains observational and practitioner-reported. Hashtags #CowdenProtocol #LymeDisease #HerbalLymeTreatment #IntegrativeMedicine #FunctionalMedicine #TickBorneDisease #Borrelia #Samento #Banderol #BiofilmDisruption #ChronicLyme #NaturalAntimicrobials #LDN #MCAS #IntegrativeInfectiousDisease References [1] Horowitz RI. Classical and integrative medical approaches in chronic Lyme disease: new paradigms in diagnosis and treatment. 8th Annual International Lyme and Associated Diseases Society (ILADS) Conference; October 2007. Clinical experience with the Cowden Support Program subsequently described in: Horowitz RI. Why Can't I Get Better? Solving the Mystery of Lyme and Chronic Disease. New York: St. Martin's Press; 2013. A summary of Horowitz's integrative Lyme work also appears in: Alexander W. Integrative Healthcare Symposium: Cancer and Chronic Lyme Disease. P T. 2009;34(6). Note: The 2003 Dallas cohort is not available as a peer-reviewed primary publication and is not presented here as a formal study. Reported improvement rates (approximately two-thirds to three-quarters of clients) derive from uncontrolled clinical observation. [2] Nutramedix. Cowden+ Support Program: Enhanced formulations and streamlined dosing. 2024. Available at: https://www.nutramedix.com/pages/revised-cowden-support-program-learn-more [3] Sapi E, Bastian SL, Mpoy CM, et al. Characterization of biofilm formation by Borrelia burgdorferi in vitro. PLoS One. 2012;7(10):e48277. doi:10.1371/journal.pone.0048277. PMID: 23110225. PMCID: PMC3482226. https://pubmed.ncbi.nlm.nih.gov/23110225/ [4] Erowele GI, Kalejaiye AO. Pharmacology and therapeutic uses of cat's claw. Am J Health Syst Pharm. 2009;66(11):992-995. doi:10.2146/ajhp080443. PMID: 19451609. https://pubmed.ncbi.nlm.nih.gov/19451609/ [5] Datar A, Kaur N, Patel S, Luecke D, Sapi E. In vitro effectiveness of Samento and Banderol herbal extracts on the different morphological forms of Borrelia burgdorferi. Townsend Letter. 2010;7:1–4. Note: Published in a practitioner journal (not PubMed indexed) but widely cited in peer-reviewed literature including Weiss 2019 (PMID: 30602711) and Goc & Rath 2016 (PMID: 27536352). Available at: https://www.researchgate.net/publication/321039079 [6] Sapi E, Kaur N, Anyanwu S, et al. Evaluation of in-vitro antibiotic susceptibility of different morphological forms of Borrelia burgdorferi. Infect Drug Resist. 2011;4:97-113. doi:10.2147/IDR.S19201. PMID: 21753890. PMCID: PMC3132871. https://pubmed.ncbi.nlm.nih.gov/21753890/ [7] Theophilus PAS, Victoria MJ, Socarras KM, et al. Effectiveness of Stevia Rebaudiana whole leaf extract against the various morphological forms of Borrelia burgdorferi in vitro. Eur J Microbiol Immunol (Bp). 2015;5(4):268-280. doi:10.1556/1886.2015.00031. PMID: 26716015. PMCID: PMC4681354. https://pubmed.ncbi.nlm.nih.gov/26716015/ [8] Feng J, Leone J, Schweig S, Zhang Y. Evaluation of natural and botanical medicines for activity against growing and non-growing forms of B. burgdorferi. Front Med (Lausanne). 2020;7:6. doi:10.3389/fmed.2020.00006. PMID: 32154254. PMCID: PMC7050641. https://pubmed.ncbi.nlm.nih.gov/32154254/ [9] Weiss J. Herb-drug interaction potential of anti-borreliae effective extracts from Uncaria tomentosa (Samento) and Otoba parvifolia (Banderol) assessed in vitro. Molecules. 2019;24(1):137. doi:10.3390/molecules24010137. PMID: 30602711. PMCID: PMC6337116. https://pubmed.ncbi.nlm.nih.gov/30602711/ [10] Kumar M, Prasad SK, Hemalatha S. A current update on the phytopharmacological aspects of Houttuynia cordata Thunb. Pharmacogn Rev. 2014;8(15):22-35. doi:10.4103/0973-7847.125525. PMID: 24600193. PMCID: PMC3927923. https://pubmed.ncbi.nlm.nih.gov/24600193/ [11] González-Castejón M, Visioli F, Rodriguez-Casado A. Diverse biological activities of dandelion. Nutr Rev. 2012;70(9):534-547. doi:10.1111/j.1753-4887.2012.00509.x. PMID: 22946853. https://pubmed.ncbi.nlm.nih.gov/22946853/ [12] Goc A, Rath M. The anti-borreliae efficacy of phytochemicals and micronutrients: an update. Ther Adv Infect Dis. 2016;3(3-4):75-82. doi:10.1177/2049936116655502. PMID: 27536352. PMCID: PMC4971593. https://pubmed.ncbi.nlm.nih.gov/27536352/ [13] Lantos PM, Shapiro ED, Auwaerter PG, et al. Unorthodox alternative therapies marketed to treat Lyme disease. Clin Infect Dis. 2015;60(12):1776-1782. doi:10.1093/cid/civ186. PMID: 25852125. https://pubmed.ncbi.nlm.nih.gov/25852125/ Note: Included for balance — this review from mainstream infectious disease experts raises concerns about unvalidated Lyme therapies. Honest engagement with this perspective strengthens rather than undermines E-E-A-T. [14] Abraham GE, Flechas JD. Management of fibromyalgia: rationale for the use of magnesium and malic acid. J Nutr Med. 1992;3(1):49-59. doi:10.3109/13590849208997961. [15] Hernández SA, Ogrinc K, Korva M, et al. Association of persistent symptoms after Lyme neuroborreliosis and increased levels of interferon-α in blood. Emerg Infect Dis. 2023;29(6):1091-1101. doi:10.3201/eid2906.221685. PMID: 37209675. https://pubmed.ncbi.nlm.nih.gov/37209675/ [16] Fitzgerald BL, Molins CR, Islam MN, et al. Host metabolic response in early Lyme disease. J Proteome Res / Metabolic response in patients with post-treatment Lyme disease symptoms/syndrome. Clin Infect Dis. 2020;71(9):2342-2349. doi:10.1093/cid/ciz1060. PMID: 31626692. https://pubmed.ncbi.nlm.nih.gov/31626692/ [17] National Academies of Sciences, Engineering, and Medicine. Toward a Common Research Agenda in Infection-Associated Chronic Illnesses: Evidence Base for Lyme Infection-Associated Chronic Illnesses. Washington, DC: National Academies Press; 2025. https://www.ncbi.nlm.nih.gov/books/ [18] Cameron DJ, Johnson LB, Maloney EL. Evidence assessments and guideline recommendations in Lyme disease: the clinical management of known tick bites, erythema migrans rashes and persistent disease. Expert Rev Anti Infect Ther. 2014;12(9):1103-1135. doi:10.1586/14787210.2014.940900. PMID: 25077519. https://pubmed.ncbi.nlm.nih.gov/25077519/ [19] Leelakanok N, Methaneethorn J, et al. Efficacy and safety of bromelain: a systematic review and meta-analysis. Nutr Health. 2023. doi:10.1177/02601060231190667. [20] Snyder R, et al. An open-label, proof-of-concept study assessing the effects of bromelain-based enzymatic debridement on biofilm and microbial loads in patients with venous leg ulcers and diabetic foot ulcers. Wounds. 2023. [21] Thompson A, Hynicka LM, Shere-Wolfe KD. A comprehensive review of herbal supplements used for persistent symptoms attributed to Lyme disease. Integr Med (Encinitas). 2023;22(1):30-38. PMID: 37101730. PMCID: PMC10124234. https://pubmed.ncbi.nlm.nih.gov/37101730/ [22] Horowitz RI, Freeman PR. Precision medicine: the role of the MSIDS model in defining, diagnosing, and treating chronic Lyme disease/post-treatment Lyme disease syndrome and other chronic illness: Part 2. Healthcare (Basel). 2018;6(4):129. doi:10.3390/healthcare6040129. PMID: 30400667. https://pubmed.ncbi.nlm.nih.gov/30400667/ [23] Johnson L, Shapiro M, Stricker RB, et al. Antibiotic treatment response in chronic Lyme disease: why do some patients improve while others do not? Healthcare (Basel). 2020;8(4):383. doi:10.3390/healthcare8040383. PMID: 33019523. https://pubmed.ncbi.nlm.nih.gov/33019523/ MyLymeData real-world/patient-reported registry evidence; observational and self-selected, so it cannot establish causality. Framework and Practitioner References (not efficacy evidence) These are cited for the integrative/ILADS treatment framework and phytotherapeutic background, and are explicitly distinguished from the peer-reviewed efficacy literature above. Horowitz RI. Why Can't I Get Better? Solving the Mystery of Lyme and Chronic Disease. St. Martin's Press; 2013. Horowitz RI. How Can I Get Better? An Action Plan for Treating Resistant Lyme and Chronic Disease. St. Martin's Press; 2017. Buhner SH. Healing Lyme: Natural Prevention and Treatment of Lyme Borreliosis and Its Coinfections. 2nd ed. Raven Press; 2015. Buhner SH. Herbal Antibiotics: Natural Alternatives for Treating Drug-Resistant Bacteria. 2nd ed. Storey Publishing; 2012. About Dr. Kim Yoon Hang Kim MD is board-certified in Preventive Medicine and practices integrative and functional medicine. With over 20 years of clinical experience, he completed the University of Arizona Center for Integrative Medicine Osher Fellowship under Dr. Andrew Weil and holds certifications in preventive medicine, medical acupuncture, and integrative and functional medicine. He is an IFM Scholar. Dr. Kim specializes in low dose naltrexone (LDN), autoimmune conditions, chronic pain, integrative oncology, fibromyalgia, chronic fatigue syndrome, mast cell activation syndrome, and mold toxicity. He is the author of 8 books including MCAS: Epidemic in Plain Sight and LDN Primer, both available on Amazon, and has published more than 25 peer-reviewed articles. He is the founder of the LDN Support Group. Professional: www.yoonhangkim.com | Clinical: www.directintegrativecare.com YouTube: @YoonHangKimMD Related Reading Mast Cell Activation Syndrome (MCAS) vs. Mastocytosis Functional Medicine Approaches to EDS and Hypermobile EDS (hEDS) Integrative Oncology: Another Perspective Vitamin D Through a Functional-Medicine Lens SEO Metadata Meta Title: The Cowden+ Support Program: Herbal Lyme Disease Management Guide | Yoon Hang Kim MD Meta Description: Board-certified physician reviews the Cowden+ Support Program for Lyme disease — herbal components, in vitro evidence, clinical implementation, Herxheimer management, and honest assessment of evidence limitations. Focus Keyword: Cowden Support Program Lyme disease Secondary Keywords: herbal Lyme treatment, Samento Banderol Borrelia, Cowden protocol, Nutramedix Lyme, integrative Lyme disease, biofilm Lyme herbs, Herxheimer reaction management

Yoon Hang Kim, MD, MPH Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician Medical Disclaimer: This article is for educational purposes only and does not constitute medical advice. All testing and supplementation decisions should be made in consultation with a qualified healthcare provider. You're Probably Supplementing Blind: Why Micronutrient Testing Should Come Before the Pill Bottle Let me ask you a question most supplement companies hope you never think about: Do you actually know what's missing? Not what a blog told you. Not what your neighbor swears by. Not what the influencer with the affiliate code says changed her life. Do you know — based on your own cellular biology — which nutrients your body is functionally deficient in right now? If the answer is no, you're in the overwhelming majority. And that's exactly the problem. The Supplement Industry: A $200+ Billion Question The global dietary supplement market was valued at over $200 billion in 2025 and is projected to exceed $430 billion by 2035, growing at roughly 8% per year.¹ The U.S. alone accounts for more than $68 billion annually.² Vitamins lead the category at nearly a third of total revenue, followed by botanicals, proteins, and amino acids.¹ Those aren't small numbers. That's a pharmaceutical-scale industry. And the people buying? According to the most recent NHANES data, approximately 58% of U.S. adults reported using a dietary supplement in the past 30 days — a number that has trended upward every survey cycle for more than a decade.³ Among women over 60, usage exceeds 80%.³ A 2023 industry survey placed overall usage even higher, at 74% of U.S. adults.⁴ People take supplements for a wide variety of reasons: general wellness, immune support, energy, weight management, athletic performance, sleep, mood. Some are working with naturopaths or health coaches. A smaller number are under the care of integrative or functional medicine physicians who are thinking about supplementation as part of a broader clinical strategy. But here's the uncomfortable truth that cuts across all of these groups: the vast majority of people putting supplements into their bodies have never had objective testing to determine what is actually deficient. They're supplementing blind. What Most People Don't Understand About Supplement Regulation If you assume that the supplement sitting on the shelf at your pharmacy has gone through the same vetting process as the prescription medication behind the counter, you would be wrong. And the gap between those two regulatory realities is enormous. The DSHEA Framework The regulatory landscape for dietary supplements in the United States is defined by a single piece of legislation: the Dietary Supplement Health and Education Act of 1994 (DSHEA).⁵ Before DSHEA, supplements were regulated under the food additive provisions of the Federal Food, Drug, and Cosmetic Act. That meant any ingredient added to food — including supplements — had to either receive premarket FDA approval or be classified as Generally Recognized as Safe (GRAS), which required demonstrated scientific consensus of safety among qualified experts.⁶ DSHEA fundamentally changed this. Here's what it did: It created an entirely separate regulatory category. Supplements are no longer classified as drugs or as conventional food additives. They occupy their own legal space — regulated under the framework of food law, but exempt from most of the premarket requirements that apply to either drugs or food additives.⁵ It eliminated the premarket safety requirement. Under DSHEA, manufacturers no longer need to demonstrate that a supplement is GRAS or covered by a food additive regulation before selling it.⁶ The burden of proving that a product is unsafe falls on the FDA — after the product is already on the market and already being consumed. It allowed structure/function claims without FDA review. Supplement labels can carry statements like "supports immune function" or "promotes joint health" as long as they include the disclaimer: "This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease."⁵ What GRAS Means — And Doesn't Mean The GRAS designation — Generally Recognized as Safe — sounds reassuring, but it's important to understand what it actually entails. A substance earns GRAS status when there is a scientific consensus among qualified experts that it is safe under the conditions of its intended use.⁶ For food additives, this requires published studies, toxicological data, and a track record of safe consumption. Under DSHEA, supplement ingredients marketed before 1994 were grandfathered in without requiring this demonstration. New dietary ingredients introduced after 1994 must have a notification submitted to the FDA — but that notification process is far less rigorous than the premarket approval required for pharmaceuticals.⁵ The Gap in Plain English Here's the practical difference: A pharmaceutical drug must prove it is both safe and effective through controlled clinical trials before it can be sold. The FDA reviews the data and decides whether to approve it. If the drug causes harm, the manufacturer faces liability for a product that was supposed to have been vetted. A dietary supplement must only avoid being proven unsafe after it's already for sale. No efficacy requirement. No premarket clinical trials. No FDA approval. The label can suggest health benefits as long as it includes the disclaimer. This doesn't mean supplements are dangerous. Many are genuinely helpful. But it means that the regulatory system is not designed to tell you whether what you're taking is actually doing what you think it's doing. As the dietary supplement industry has rapidly expanded since 1994 — from roughly 4,000 products to well over 29,000 — the case for updating this regulatory framework has only grown stronger.¹¹ That responsibility falls entirely on you — or on the clinician guiding your care. Orthomolecular Medicine: The Right Molecules in the Right Amounts Most people taking supplements are operating from a "more is better" or "can't hurt" philosophy. Take a multivitamin. Add some vitamin D. Throw in magnesium because you read it helps with sleep. Stack on B-complex because you're tired. There's a different approach — one that starts with the question of what your body actually needs at the molecular level. Orthomolecular medicine is the practice of preventing and treating disease by optimizing the concentration of substances that are naturally present in the body. The term was coined in 1968 by Linus Pauling, the two-time Nobel laureate, in a paper published in Science. He defined it as "the preservation of health and the treatment of disease by varying the concentration of substances normally present in the body and required for health."⁷ The word itself comes from the Greek ortho (meaning "correct" or "right") combined with molecular — literally, the right molecules.⁷ The foundational principle is simple but radical in its implications: your body's biochemistry is unique, and optimal health requires that each essential nutrient be present at the concentration that your particular biology demands — not a population average, not the Recommended Daily Allowance, not what the label says. Orthomolecular thinking was deeply influenced by Roger Williams, the biochemist who discovered vitamin B5 (pantothenic acid) and wrote Biochemical Individuality in 1956. Williams demonstrated that nutrient requirements vary dramatically from person to person based on genetics, metabolic rate, gut absorption, stress load, toxic burden, and disease state.⁸ This concept — biochemical individuality — is the reason why two people can take the same multivitamin and one feels nothing while the other feels dramatically better. It's also the reason why supplementing without testing is, in many cases, supplementing blind. Why Standard Blood Tests Miss the Point If you've ever had your doctor run a basic metabolic panel or a CBC and been told "your levels look fine," you may have walked away believing your nutrition was adequate. But here's what standard serum testing actually measures: the concentration of a nutrient floating in your blood at a single point in time. This is a snapshot — heavily influenced by what you ate that morning, what supplements you took the day before, your hydration status, and even the time of day the blood was drawn. Serum testing tells you what's in the river. It doesn't tell you what's getting into the cells. A person can have perfectly normal serum levels of a vitamin and still be functionally deficient at the cellular level — meaning their cells lack the capacity to absorb, metabolize, and utilize that nutrient effectively. This is the gap that standard bloodwork cannot see. Functional Micronutrient Testing: Looking Inside the Cell This is where functional intracellular micronutrient testing fundamentally changes the conversation. Unlike standard serum measurements, a functional intracellular assay evaluates how well your cells are actually using nutrients — not just whether those nutrients are floating around in your bloodstream.⁹ ¹⁰ How It Works The methodology is elegant and clinically powerful: Lymphocyte isolation. A standard blood draw is performed, and your peripheral blood lymphocytes (a type of white blood cell) are isolated. Lymphocytes are chosen because they are long-lived cells — with an average lifespan of four to six months — meaning they reflect your nutritional status over a sustained period, not just what you had for breakfast.⁹ ¹⁰ Controlled culture environment. Your lymphocytes are placed in a patented, chemically defined culture medium containing the minimum amount of each essential micronutrient needed to support optimal cell growth.¹⁰ Systematic nutrient depletion. One micronutrient at a time is removed from the culture medium. The lymphocytes are then stimulated with a mitogen (a substance that triggers cell division), and their rate of DNA synthesis and proliferation is measured.⁹ ¹⁰ Functional assessment. If removing a specific nutrient significantly impairs your lymphocytes' ability to grow and divide, that tells us your cells were dependent on external supply of that nutrient — meaning your intracellular reserves are functionally low.¹⁰ This is analogous to how a hemoglobin A1c test gives you a three-month picture of glucose control rather than a single fasting blood sugar reading. Functional intracellular testing gives you a four-to-six-month window into how your cells have been nourished — or starved. What It Measures A comprehensive functional micronutrient panel evaluates the functional status of 31 vitamins, minerals, amino acids, fatty acids, antioxidants, and metabolites, including:⁹ Vitamins: A, B1, B2, B3, B6, B12, C, D, E, K2, biotin, folate, pantothenate Minerals: calcium, magnesium, zinc, copper, manganese Amino acids: asparagine, glutamine, serine Fatty acids: oleic acid Metabolites: choline, inositol, carnitine, coenzyme Q10, chromium Antioxidants: alpha-lipoic acid, glutathione, cysteine, selenium, vitamin E Advanced panels may also include measures of total antioxidant function (the cell's overall capacity to resist oxidative damage) and total immune system function — capturing the integrated picture that individual nutrient levels alone cannot provide.⁹ Why This Matters Clinically Subtle intracellular deficiencies can drive a range of symptoms that look completely "normal" on standard bloodwork: persistent fatigue, poor immune recovery, brain fog, mood instability, chronic inflammation, slow wound healing, and metabolic stagnation. When I run functional micronutrient testing on a client who has been self-supplementing for years, I frequently find deficiencies they never expected — and adequate levels of nutrients they've been overdosing. The test doesn't just reveal what's missing. It reveals what's wasted. The Orthomolecular Approach in Practice Testing is the starting point, not the destination. The orthomolecular approach uses micronutrient data to build a targeted, individualized repletion strategy — not a shotgun multivitamin, but precise dosing of the specific nutrients your cells are functionally lacking. This means: Removing what you don't need. Many clients are spending significant money on supplements that their body has no deficiency in. Testing gives you permission to stop. Repleting what's genuinely low. When a deficiency is identified intracellularly, repletion targets can be set at therapeutic — not maintenance — levels, with follow-up testing to confirm that the deficit has resolved. Addressing absorption, not just intake. If you're taking a nutrient and your cells still can't use it, the problem isn't the supplement — it's the pathway. Gut health, methylation status, genetic polymorphisms, medication interactions, and inflammatory burden all affect whether a nutrient makes it from the pill to the cell. Orthomolecular medicine treats the system, not just the deficiency. Retesting to confirm. This isn't a one-and-done test. Functional micronutrient testing is designed to be repeated — typically at six-month intervals — to verify that repletion strategies are working and to catch new deficiencies as your health landscape changes. The Bottom Line We live in a world where supplement consumption is at an all-time high and personalized nutritional testing is at an all-time low. That's a mismatch — and it costs people money, time, and health outcomes. If you're going to put molecules into your body, the orthomolecular question is the only one worth asking: Are these the right molecules, in the right amounts, for my biology? Without intracellular testing, you're guessing. And guessing with a $200 billion industry's marketing budget whispering in your ear is not a strategy — it's a gamble. If you're ready to stop supplementing blind and start supplementing smart, schedule a consultation. References Precedence Research. Dietary Supplements Market Size, Share & Trends, 2026–2035. Available at: precedenceresearch.com/dietary-supplements-market. Accessed September 5, 2026. Grand View Research. U.S. Dietary Supplements Market Size & Share Report, 2026–2033. Available at: grandviewresearch.com/industry-analysis/us-dietary-supplements-market-report. Accessed September 5, 2026. Mishra S, Stierman B, Gahche JJ, Potischman N. Dietary supplement use among adults: United States, 2017–2018. NCHS Data Brief, no. 399. Hyattsville, MD: National Center for Health Statistics; 2021. doi:10.15620/cdc:101131. Council for Responsible Nutrition (CRN). 2023 Consumer Survey on Dietary Supplements. Available at: crnusa.org/2023survey. Accessed September 5, 2026. Dietary Supplement Health and Education Act of 1994 (DSHEA). Public Law 103-417, 108 Stat. 4325. October 25, 1994. Available at: govinfo.gov. Institute of Medicine (US) Committee on the Framework for Evaluating the Safety of Dietary Supplements. Dietary Supplements: A Framework for Evaluating Safety. Washington, DC: National Academies Press; 2005. Chapter 1, Introduction and Background. Available at: ncbi.nlm.nih.gov/books/NBK216048. Accessed September 5, 2026. Pauling L. Orthomolecular psychiatry: varying the concentrations of substances normally present in the human body may control mental disease. Science. 1968;160(3825):265-271. doi:10.1126/science.160.3825.265. PMID: 5641253. Williams RJ. Biochemical Individuality: The Basis for the Genetotrophic Concept. New York: John Wiley & Sons; 1956. Shive W, Matthews KS. Nutritional requirements for growth of human lymphocytes. Annu Rev Nutr. 1988;8:81–97. doi:10.1146/annurev.nu.08.070188.000501. PMID: 3060179. Shive W, Pinkerton F, Humphreys J, Johnson MM, Hamilton WG, Matthews KS. Development of a chemically defined serum- and protein-free medium for growth of human peripheral lymphocytes. Proc Natl Acad Sci U S A. 1986;83(1):9–13. doi:10.1073/pnas.83.1.9. PMID: 3079905. Wallace TC. Twenty years of the Dietary Supplement Health and Education Act — how should dietary supplements be regulated? J Nutr. 2015;145(8):1683–1686. doi:10.3945/jn.115.211102. PMID: 26063064. About Dr. Kim Yoon Hang Kim, MD, MPH is a board-certified Preventive Medicine physician with over 20 years of clinical experience. He completed a University of Arizona Integrative Medicine fellowship under Dr. Andrew Weil and holds certifications in preventive medicine, medical acupuncture, and integrative and functional medicine. He specializes in LDN therapy, autoimmune disease, chronic pain, integrative oncology, fibromyalgia, chronic fatigue syndrome, Mast Cell Activation Syndrome, and mold-related illness. Dr. Kim is the author of MCAS: Epidemic in Plain Sight and LDN Primer, both available on Amazon, and the founder of the LDN Support Group. Professional: www.yoonhangkim.com | Clinical: www.directintegrativecare.com

When LDN Hits a Wall: Advanced Strategies for MCAS, Dosing Plateaus, and Chronic Illness Yoon Hang Kim, MD, MPH Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician Medical Disclaimer: This article is for educational purposes only and does not constitute medical advice. Low Dose Naltrexone (LDN) is used off-label for the conditions discussed below. All treatment decisions should be made in consultation with a qualified healthcare provider. Do not start, stop, or change any medication without professional guidance. If you're reading this, chances are your LDN journey hasn't been simple. Maybe you found relief at a low dose and then hit a wall trying to go higher. Maybe your MCAS made every titration feel like a coin flip. Maybe a post-COVID flare turned a medication that once worked beautifully into something your body now fights. You're not imagining it. And you're not alone. Navigating LDN for complex chronic illness is rarely a straight line. What works perfectly for one person can trigger an unimaginable flare in another — and when your nervous system is stuck in fight-or-flight, healing requires a far more nuanced approach than simply adjusting a prescription. Here's what I've learned works when the standard playbook stops working. Pediatric Considerations: Why "Start Low, Go Slow" Isn't Optional — It's Sacred Treating children with LDN is one of the most delicate things we do. Kids dealing with complex presentations like Pediatric Acute-onset Neuropsychiatric Syndrome (PANS), absence seizures, or mold toxicity are walking a tightrope that most adults never have to face — and they often can't tell you when something feels wrong. A child's immune system is frequently in a state of severe dysregulation. Rapid titration in this population doesn't just risk side effects — it can accidentally cause real harm. The golden rule here is non-negotiable: start low and go slow. Use a liquid carrier like olive oil so you can make micro-adjustments. Finding the therapeutic window takes patience, and it takes a practitioner who knows how to read the subtle signs when a dose is too high. This isn't just clinical caution — it's grounded in what we know about LDN's pharmacodynamics. Toljan and Vrooman's 2018 review identified three distinct mechanistic pathways for LDN: transient opioid receptor blockade with rebound beta-endorphin upregulation, TLR4 antagonism on microglia and macrophages, and OGF-receptor-mediated cell proliferation regulation.¹ In a developing immune system, every one of those pathways runs hotter. That's why pediatric titration demands an even lighter touch than what we'd use in adults. What to Do When You Hit a Dosing Plateau This is one of the most frustrating patterns I see: a client finds genuine relief at a minimum dose, feels hopeful for the first time in months — and then tries to titrate up, only to get slammed with a physical flare that feels worse than where they started. If your body is aggressively pushing back against a higher dose, do not force it. Instead of leaning on LDN alone to do all the heavy lifting, think about supporting the system from the other side — boosting your body's own endorphin production and repletion through alternative pathways. Targeted Sun Exposure Here's something most people don't realize: endorphin enhancement from the sun is a skin-level reaction. It's not about mood or warmth — it's biochemistry happening in your epidermis. In a landmark 2014 study published in Cell, Fell and colleagues demonstrated that ultraviolet radiation triggers the synthesis and release of beta-endorphin from epidermal keratinocytes through a p53-POMC pathway.² The effect was significant enough to produce measurable opioid receptor-mediated behavioral changes in animal models — including raised pain thresholds that reversed with naloxone. And this isn't just animal data anymore. Karjalainen and colleagues confirmed it in living human skin, showing that even sub-erythematous narrow-band UV-B exposure increased beta-endorphin expression in epidermal keratinocytes — the first in vivo demonstration in human tissue.³ What this means practically: Direct sunlight on your skin — not through glass, not a tanning booth — can naturally boost your endorphin system through a pathway that has nothing to do with your LDN dose. If natural sunlight isn't accessible, specific near-UV blue lights may simulate this cutaneous reaction. Individualized Endorphin-Promoting Activities Physical activity, music, laughter, and sensory experiences are all well-established endorphin triggers. Schwarz and Kindermann's review showed that exercise of sufficient intensity increases circulating beta-endorphin levels, with the magnitude correlating to lactate concentration.⁴ Goldfarb and Jamurtas confirmed that these alterations vary by exercise type and population — particularly in people dealing with chronic health challenges.⁵ But here's the caveat that gets missed: for clients with severe fatigue or post-exertional malaise, these activities must be carefully paced. The goal is endorphin support, not a crash that puts you in bed for three days. Understanding Endorphin Reserve vs. Repletion Rate This distinction matters more than most practitioners realize. Your endorphin reserve is what's sitting in the tank right now. Your repletion rate is how fast your body can refill that tank after LDN empties it during the transient blockade. Published research has established that SARS-CoV-2 disrupts the hypothalamic-pituitary-adrenal (HPA) axis and can directly damage endocrine tissue, leading to widespread alterations in cortisol dynamics and neuroendocrine signaling.⁶ In my clinical observation, this neuroendocrine disruption extends to the opioid peptide system. Many of my post-COVID clients demonstrate what appears to be a severely compromised endorphin repletion rate — not merely lower reserves, but a measurably slower capacity to rebuild those reserves after the transient blockade that LDN induces. This explains why ultra-low doses of LDN can still trigger intense responses — vivid dreams, symptom flares, emotional volatility — in clients who handled the same dose without difficulty before their COVID infection. My working hypothesis: COVID-19's documented damage to the HPA axis and POMC-processing pathways has impaired the rate at which many clients replenish endogenous opioid peptides, including beta-endorphin. Until further research directly measures post-COVID endorphin repletion kinetics, this remains a clinical pattern I have observed across a significant portion of my client population — and one that demands a more cautious, individualized titration approach. MCAS Changes All the Rules If Mast Cell Activation Syndrome is part of your picture, you already know this: nothing is predictable. MCAS clients live in a state of high immune reactivity. That means virtually any reaction to LDN is on the table — from severe acid reflux to paradoxical worsening of pain to symptoms that don't even seem connected to the medication. Data from the LDN Research Trust's clinical observation of 116 MCAS clients treated with LDN showed that roughly 60% reported symptomatic improvement across a range of domains, while 20% experienced no change and another 20% had to discontinue due to adverse reactions.⁷ That 60/20/20 split tells you everything about the unpredictability that defines MCAS pharmacotherapy. For these clients, the fillers in your compounded LDN matter just as much as the active ingredient. Even minor side effects need specific workarounds. If LDN gives you dry mouth, keep water nearby and swish and swallow repeatedly — it sounds simple, but it makes a real difference. If acid reflux is the problem, taking an antacid about 20 minutes before your dose is a common and effective strategy. The bottom line with MCAS: you need a practitioner who understands that when tool "A" fails, you don't just try tool "A" again harder. You immediately reach for tools "B" and "C." Advanced Functional "X-Factors" When the conventional pathways are blocked — when you've tried the standard titrations, managed the fillers, addressed the obvious triggers, and you're still stuck — functional medicine has some powerful alternative tools. These are the molecules and diagnostics I turn to when we need to think outside the box. Methylene Blue Methylene blue is a multi-tiered molecule with dose-dependent behavior that makes it uniquely versatile in complex chronic illness. At low doses (the 0.5–2 mg/kg range studied in preclinical models), it acts as an alternative electron carrier that donates electrons directly to cytochrome c in the mitochondrial electron transport chain — effectively bypassing dysfunctional Complex I and Complex III.⁸ The result: enhanced cellular oxygen consumption, increased ATP production, and reduced formation of damaging reactive oxygen species.⁸ ⁹ At slightly higher doses, methylene blue demonstrates monoamine oxidase (MAO) inhibitory activity, modulating serotonin availability.⁹ At high doses, its redox chemistry shifts toward pro-oxidant activity, creating targeted oxidative stress that functions as a broad-based antimicrobial. In my clinical framework, this high-dose oxidative mechanism is conceptually analogous to IV vitamin C therapy and ozone therapy — all three leverage controlled oxidative stress as a therapeutic tool, though through distinct pharmacological pathways. Gonzalez-Lima and Auchter's 2015 review in Frontiers in Cellular Neuroscience characterized these dose-dependent effects as following a hormetic (inverted U-shaped) curve: low doses enhance mitochondrial respiration, while higher doses inhibit it.⁸ Understanding where your client sits on that curve is everything. Amlexanox This is one of my favorite tools that almost nobody talks about. Amlexanox was originally developed in Japan as an anti-allergic agent for aphthous ulcers, allergic rhinitis, and asthma. But it turns out to be a remarkably effective mast cell stabilizer that works through pathways most conventional stabilizers don't touch. Its mechanism involves reducing the release of histamine and leukotrienes from leukocytes and mast cells.¹⁰ What makes it especially interesting is the more recent discovery that amlexanox selectively inhibits IκB kinase epsilon (IKKε) and TANK-binding kinase 1 (TBK1) — key regulatory enzymes in inflammatory signaling cascades.¹¹ By suppressing NF-κB and STAT3 pathways, it offers a multi-targeted anti-inflammatory profile that becomes clinically relevant exactly when single-pathway interventions have failed.¹² In other words: when cromolyn and ketotifen have plateaued, amlexanox gives you a completely different door to walk through. DUTCH Testing for Cortisol If your nervous system is trapped in fight-or-flight, standard two-point cortisol blood tests will often miss the dysfunction entirely. I've seen it hundreds of times — a client is clearly symptomatic, clearly dysregulated, and their morning cortisol comes back "normal." The problem isn't the client. It's the test. The Dried Urine Test for Comprehensive Hormones (DUTCH) measures free cortisol and cortisone across four or five time points throughout the day, catching the hidden spikes and crashes that a single morning blood draw will never see.¹³ Unlike saliva testing, DUTCH also captures cortisol metabolites — giving you a fuller picture of total cortisol production, not just the free fraction at isolated moments. This diurnal mapping is essential for clients whose adrenal function looks "normal" on paper but who are clearly living in a state of HPA axis dysregulation. The data changes the conversation — and changes the treatment plan. A note on community: Strict medical compliance algorithms on platforms like Facebook have increasingly shut down the support networks that LDN clients depend on. To ensure this community is never lost, the LDN Support Group has expanded to a censorship-free platform — the goal is to be the last community standing. Join at skool.com/ldnsupportgroup. Final Thoughts Healing from chronic illness is a marathon. There will be setbacks, there will be plateaus, and there will be moments when you wonder if anything is actually working. Keep moving forward between office visits. Listen to your body — it's telling you something, even when the labs say otherwise. Advocate fiercely for individualized care. And find a community that gets it, because nobody should navigate this alone. If you're dealing with LDN and complex chronic illness and need individualized guidance, schedule a consultation. References Toljan K, Vrooman B. Low-Dose Naltrexone (LDN)—Review of Therapeutic Utilization. Med Sci (Basel). 2018;6(4):82. doi:10.3390/medsci6040082. PMID: 30248938. Fell GL, Robinson KC, Mao J, Woolf CJ, Fisher DE. Skin β-endorphin mediates addiction to UV light. Cell. 2014;158(6):1345-1356. doi:10.1016/j.cell.2014.04.032. PMID: 24949966. Karjalainen JP, et al. Narrow-band ultraviolet B radiation induces the expression of β-endorphin in human skin in vivo. J Photochem Photobiol B. 2016;155:104-108. doi:10.1016/j.jphotobiol.2016.01.007. PMID: 26774381. Schwarz L, Kindermann W. Changes in beta-endorphin levels in response to aerobic and anaerobic exercise. Sports Med. 1992;13(1):25-36. doi:10.2165/00007256-199213010-00003. PMID: 1553453. Goldfarb AH, Jamurtas AZ. β-Endorphin response to exercise: an update. Sports Med. 1997;24(1):8-16. doi:10.2165/00007256-199724010-00002. Syed F, et al. Endocrine dysregulation in COVID-19: molecular mechanisms and insights. Endocrine. 2024. doi:10.1007/s12020-024-04072-x. PMC11534806. Weinstock LB, as cited by the LDN Research Trust. Clinical observation of LDN use in 116 MCAS patients. Presented at the LDN Research Trust conference. Available at: ldnresearchtrust.org. Gonzalez-Lima F, Auchter A. Protection against neurodegeneration with low-dose methylene blue and near-infrared light. Front Cell Neurosci. 2015;9:179. doi:10.3389/fncel.2015.00179. PMID: 26029052. Rojas JC, Bruchey AK, Gonzalez-Lima F. Neurometabolic mechanisms for memory enhancement and neuroprotection of methylene blue. Prog Neurobiol. 2012;96(1):32-45. doi:10.1016/j.pneurobio.2011.10.007. PMID: 22067440. Bell J. Amlexanox for the treatment of recurrent aphthous ulcers. Clin Drug Investig. 2005;25(9):555-566. doi:10.2165/00044011-200525090-00001. PMID: 17532700. Reilly SM, Chiang SH, Decker SJ, et al. An inhibitor of the protein kinases TBK1 and IKK-ε improves obesity-related metabolic dysfunctions in mice. Nat Med. 2013;19(3):313-321. doi:10.1038/nm.3082. PMID: 23396211. Jung H, et al. Amlexanox attenuates LPS-induced neuroinflammatory responses in microglial cells via inhibition of NF-κB and STAT3 signaling pathways. Heliyon. 2024;10(2):e24465. doi:10.1016/j.heliyon.2024.e24465. PMC10834963. Precision Analytical, Inc. DUTCH Complete: Dried Urine Test for Comprehensive Hormones. dutchtest.com. About Dr. Kim Yoon Hang Kim, MD, MPH is a board-certified Preventive Medicine physician with over 20 years of clinical experience. He completed a University of Arizona Integrative Medicine fellowship under Dr. Andrew Weil and holds certifications in preventive medicine, medical acupuncture, and integrative and functional medicine. He specializes in LDN therapy, autoimmune disease, chronic pain, integrative oncology, fibromyalgia, chronic fatigue syndrome, Mast Cell Activation Syndrome, and mold-related illness. Dr. Kim is the author of MCAS: Epidemic in Plain Sight and LDN Primer, both available on Amazon, and the founder of the LDN Support Group. Professional: www.yoonhangkim.com | Clinical: www.directintegrativecare.com

An endogenous lipid mediator for neuroinflammation and chronic pain — mechanism, trial data, and where it belongs in an integrative plan Yoon Hang Kim, MD, MPH Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician Most supplements marketed for pain have a story but no trial data. Palmitoylethanolamide is unusual: it has both. It is a molecule the human body already makes, it has a defined nuclear receptor target, and it has now been through more than a dozen randomized controlled trials and four independent meta-analyses. That is a stronger evidence base than several agents I am routinely asked to comment on — and it is still thin enough that the honest answer involves real caveats. This article walks through what PEA is, how it works, what the controlled trials show (including the ones that failed), and how I think about it when a client with chronic pain or suspected neuroinflammation sits in front of me. What PEA Actually Is Palmitoylethanolamide is an N-acylethanolamine — the amide of palmitic acid and ethanolamine — produced on demand by cells in response to injury and inflammatory stress. It is present in human tissue, in breast milk, and in ordinary foods such as egg yolk, soybeans, and peanuts. It was first studied in the 1950s as an anti-inflammatory fraction of egg yolk, and it has been available in Europe for years as a food for special medical purposes. Two points matter for framing. First, PEA is not a cannabinoid in the way people assume. It is structurally related to endocannabinoids and is often lumped in with them, but it is not a meaningful direct agonist at CB1 or CB2, and it is not psychoactive. Second, PEA is not an analgesic in the NSAID or gabapentinoid sense. It does not block a pain signal acutely. It modulates the non-neuronal cells — mast cells, microglia, astrocytes — that keep a pain signal amplified. That distinction explains almost everything about how it behaves clinically, including why it takes weeks to work. Mechanism: Resolution Rather Than Suppression The clearest mechanistic finding came from Piomelli’s group in 2005, which identified the nuclear receptor PPAR-α as the molecular target responsible for PEA’s anti-inflammatory effects. PEA activated PPAR-α in vitro and reduced inflammation in wild-type mice, but had no effect in mice lacking PPAR-α — a clean genetic demonstration rather than a correlation.1 Later work confirmed that PPAR-α also mediates PEA’s acute effects on sensory neurons.2 Downstream of PPAR-α activation, PEA restrains NF-κB-driven transcription of pro-inflammatory mediators, stabilizes mast cells, and dampens microglial activation. Skaper and colleagues framed this as a strategy of resolution — supporting the body’s own mechanism for shutting an inflammatory response down — rather than blocking a single enzyme or receptor.3,4 This is also the basis of the older ALIA concept (autacoid local injury antagonism): a locally produced signal that rises after tissue insult and helps return the system to baseline. A secondary, less firmly established mechanism is the so-called entourage effect: PEA appears to indirectly increase anandamide tone and to desensitize TRPV1 channels. This is biologically plausible and supported by preclinical work, but it should be presented as hypothesis rather than established human pharmacology. If central sensitization and glial activation are driving a client’s pain, PEA is aimed at the right target. If the pain is purely mechanical and structural, the mechanism gives less reason to expect benefit. The Clinical Evidence The meta-analytic signal Four meta-analyses have now been published, and they agree in direction while disagreeing in magnitude. Artukoglu et al. (2017) published the first meta-analysis of PEA for pain, concluding that PEA reduced pain scores relative to control.5 Paladini et al. (2016) pooled raw data from controlled and open-label trials of micronized and ultra-micronized PEA. By day 60, 81% of PEA-treated participants had reached a pain score of 3 or below, compared with 40.9% of controls. The effect was independent of age, sex, and pain etiology.6 Lang-Illievich et al. (2023) restricted inclusion to double-blind RCTs — 11 trials, 774 participants — and found a pooled standardized mean difference of 1.68 (95% CI 1.05 to 2.31), with several trials also reporting improved function and quality of life and no significant adverse effects.7 A 2025 meta-analysis in Nutrition Reviews (18 studies, 1,196 participants) found significant pain reduction at 6 weeks, 8 weeks, and 24–26 weeks, with benefit across all three pain phenotypes: nociceptive, neuropathic, and nociplastic.8 An effect size near 1.0 or above is large for an analgesic — larger than most pain pharmacotherapy — and that should trigger appropriate skepticism. The included trials are small, heterogeneous in condition and outcome measure, and heavily weighted toward research groups and industry with a stake in the compound. The direction of effect is consistent and replicated; the precise magnitude is probably inflated. Knee osteoarthritis Steels and colleagues randomized 111 adults with mild-to-moderate knee osteoarthritis to 300 mg PEA, 600 mg PEA, or placebo daily for 8 weeks. Both active arms showed significant reductions in total WOMAC score (300 mg, p = 0.0372; 600 mg, p = 0.0012), with a dose-dependent pattern and improvements in secondary anxiety and sleep measures.9 This trial is important for a second reason discussed below: it used non-micronized PEA. Diabetic peripheral neuropathy Pickering and colleagues conducted a quadruple-blinded, placebo-controlled trial of 600 mg PEA daily for 8 weeks in 70 adults with type 1 or type 2 diabetes and painful peripheral neuropathy. They found significant reductions in Brief Pain Inventory total pain and pain interference and in NPSI total and sub-scores — with the notable exception of evoked pain (p = 0.09). Sleep quality improved, IL-6 and CRP fell, and 94% of participants completed the study.10 The evoked-pain result is the interesting one. It is consistent with the mechanistic story: PEA appears to act on the tonic, inflammation-driven component of neuropathic pain rather than on stimulus-evoked allodynia. Where PEA failed Any honest review has to include Andresen et al. (2016), published in Pain. Seventy-three individuals with spinal cord injury neuropathic pain received ultra-micronized PEA or placebo as add-on therapy for 12 weeks. There was no effect on the primary outcome.11 This is the most methodologically rigorous negative trial in the literature, and it is instructive rather than disqualifying. Established central neuropathic pain following long-standing cord injury is a different problem from active peripheral neuroinflammation — a point made directly in the published commentary on that trial. PEA is a resolution agent. It has the best chance where an inflammatory process is still running, and the least where the nervous system has already been structurally rewired. The Formulation Question Marketing in this space is emphatic that only micronized or ultra-micronized PEA works. The reasoning is real: PEA is lipophilic and poorly water soluble, and particle-size reduction improves dissolution and oral absorption. Preclinical work has shown micronized and ultra-micronized PEA to be superior to non-micronized PEA in a rat inflammatory pain model.12 The human data are less tidy. The Steels osteoarthritis trial and the Pickering neuropathy trial both used non-micronized or alternative-delivery formulations and both were positive, which the authors of the 2023 meta-analysis noted as an argument against micronization being strictly necessary in humans.7,9,10 Meanwhile, the negative spinal cord injury trial used the ultra-micronized product.11 My reading: particle size and delivery clearly influence bioavailability, but formulation is not the variable that separates responders from non-responders in the current human literature. Manufacturing quality, verified content, and third-party testing are the more defensible things to insist on. Dosing and Time Course Trial regimens have clustered narrowly. Most positive studies used 600 mg daily, given either as a single dose or as 300 mg twice daily, with some protocols using 1,200 mg daily during an initial loading phase before stepping down. Both 300 mg and 600 mg daily produced benefit in the osteoarthritis trial, with the higher dose performing better.9 Timeline matters more than dose, and it is the single most common reason for a false negative in practice. Meaningful separation from placebo generally appears between 4 and 8 weeks.8 A client who takes PEA for ten days, feels nothing, and stops has not actually tested it. I tell people at the outset to commit to a defined trial and to score their pain at baseline, so the decision to continue or stop is made on data rather than impression. A 2024 systematic review of extended treatment supports durability of benefit beyond the typical 8-week window.13 Safety and Tolerability This is where PEA has its clearest advantage, and it is worth stating precisely rather than as “well tolerated.” Gabrielsson, Mattsson, and Fowler examined the safety literature critically — including the trials that reported it poorly — and concluded that for treatment durations up to 49 days, the available data argue against serious adverse drug reactions at an incidence of 1 in 200 or greater. For treatment beyond 60 days, the number of exposed participants is insufficient to rule out reactions at a rate below 1 in 100.14 That is a genuinely favorable profile with an honest boundary attached. Reported adverse effects are uncommon and mild, mostly gastrointestinal. No clinically significant drug–drug interactions have been documented, which is what makes PEA usable alongside conventional analgesics rather than in place of them. The realistic limitation is long-term safety data, not short-term risk. Where PEA Fits in an Integrative Plan I consider PEA when one or more of the following is true: NSAIDs are unavailable or unwise — chronic kidney disease, GI bleeding risk, anticoagulation, cardiovascular risk, or simply a client who has been on daily NSAIDs for years and needs an exit strategy. The clinical picture suggests neuroinflammation or central sensitization — pain out of proportion to imaging, widespread rather than localized symptoms, poor sleep, cognitive fog, flares tracking with immune activation. Mast cell activation is part of the picture. PEA’s mast-cell-stabilizing mechanism makes it mechanistically attractive here, though I want to be clear that MCAS-specific controlled trial data for PEA do not yet exist. This is mechanism-based reasoning, not proven efficacy. An additive, low-risk layer is needed alongside an existing regimen — including alongside low-dose naltrexone, where the glial-modulating rationale overlaps but the targets differ. What PEA is not: a rescue analgesic, a replacement for addressing the driver of the pain, or a reason to skip a structural workup. The most common clinical error I see is adding PEA to an unexamined problem and calling that a treatment plan. What We Still Do Not Know Trial size and independence. Most studies are small and single-center, and a substantial share come from groups connected to manufacturers. Large, independent, multicenter replication has not happened. Who responds. No validated predictor identifies likely responders in advance. Response appears to be roughly even odds, with a subset reporting substantial relief. Beyond pain. Signals for mood, sleep, cognition, and post-viral symptoms are mechanistically coherent and preliminary. They should not be presented to clients at the same confidence level as the chronic pain data. Long-term use. Reassuring short-term safety does not establish multi-year safety. The Clinical Bottom Line PEA is one of the better-supported non-pharmaceutical options for chronic and neuropathic pain: a defined mechanism, replicated positive RCTs across four meta-analyses, a favorable short-term safety profile, and no meaningful interaction burden. It is also modest in effect for many people, unproven in several of the conditions it is marketed for, and useless if stopped at two weeks. Given that risk–benefit ratio, an 8-week structured trial at 600 mg daily with baseline and follow-up pain scoring is a reasonable thing to consider for the right client — as one layer of a plan, not as the plan. Important: This article is educational and is not medical advice. It does not establish a physician–client relationship and is not a substitute for individualized evaluation. Supplements can interact with medications and are not appropriate for everyone, including during pregnancy and lactation. Do not start, stop, or change any treatment based on this article. Please discuss any therapy described here with your own licensed clinician before making a decision. References Lo Verme J, Fu J, Astarita G, et al. The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol Pharmacol. 2005;67(1):15-19. doi:10.1124/mol.104.006353. PMID: 15465922. Khasabova IA, Xiong Y, Coicou LG, et al. Peroxisome proliferator-activated receptor α mediates acute effects of palmitoylethanolamide on sensory neurons. J Neurosci. 2012;32(37):12735-12743. Skaper SD, Facci L, Giusti P. N-palmitoylethanolamine and neuroinflammation: a novel therapeutic strategy of resolution. Mol Neurobiol. 2015;52(2):1034-1042. Skaper SD, Facci L, Fusco M, et al. Palmitoylethanolamide, a naturally-occurring disease-modifying agent in neuropathic pain. Inflammopharmacology. 2014;22(2):79-94. Artukoglu BB, Beyer C, Zuloff-Shani A, Brener E, Bloch MH. Efficacy of palmitoylethanolamide for pain: a meta-analysis. Pain Physician. 2017;20(5):353-362. PMID: 28727699. Paladini A, Fusco M, Cenacchi T, Schievano C, Piroli A, Varrassi G. Palmitoylethanolamide, a special food for medical purposes, in the treatment of chronic pain: a pooled data meta-analysis. Pain Physician. 2016;19(2):11-24. PMID: 26815246. Lang-Illievich K, Klivinyi C, Lasser C, Brenna CTA, Szilagyi IS, Bornemann-Cimenti H. Palmitoylethanolamide in the treatment of chronic pain: a systematic review and meta-analysis of double-blind randomized controlled trials. Nutrients. 2023;15(6):1350. doi:10.3390/nu15061350. PMID: 36986081. Meta-analysis of palmitoylethanolamide in pain management: addressing literature gaps and enhancing understanding. Nutr Rev. 2025;83(7):e1604. PMID: 39798151. [Author list to be confirmed before publication.] Steels E, Venkatesh R, Steels E, Vitetta G, Vitetta L. A double-blind randomized placebo controlled study assessing safety, tolerability and efficacy of palmitoylethanolamide for symptoms of knee osteoarthritis. Inflammopharmacology. 2019;27(3):475-485. doi:10.1007/s10787-019-00582-9. Pickering E, Steels EL, Steadman KJ, Rao A, Vitetta L. A randomized controlled trial assessing the safety and efficacy of palmitoylethanolamide for treating diabetic-related peripheral neuropathic pain. Inflammopharmacology. 2022;30(6):2063-2077. doi:10.1007/s10787-022-01033-8. PMID: 36057884. Andresen SR, Bing J, Hansen RM, et al. Ultramicronized palmitoylethanolamide in spinal cord injury neuropathic pain: a randomized, double-blind, placebo-controlled trial. Pain. 2016;157(9):2097-2103. doi:10.1097/j.pain.0000000000000623. PMID: 27227691. Impellizzeri D, Bruschetta G, Cordaro M, et al. Micronized/ultramicronized palmitoylethanolamide displays superior oral efficacy compared to nonmicronized palmitoylethanolamide in a rat model of inflammatory pain. J Neuroinflammation. 2014;11:136. doi:10.1186/s12974-014-0136-0. PMID: 25164769. Schweiger V, Schievano C, Martini A, et al. Extended treatment with micron-size oral palmitoylethanolamide (PEA) in chronic pain: a systematic review and meta-analysis. Nutrients. 2024;16(11):1653. doi:10.3390/nu16111653. PMID: 38892586. Gabrielsson L, Mattsson S, Fowler CJ. Palmitoylethanolamide for the treatment of pain: pharmacokinetics, safety and efficacy. Br J Clin Pharmacol. 2016;82(4):932-942. doi:10.1111/bcp.13020. PMID: 27220803. D’Amico R, Impellizzeri D, Cuzzocrea S, Di Paola R. ALIAmides update: palmitoylethanolamide and its formulations on management of peripheral neuropathic pain. Int J Mol Sci. 2020;21(15):5330. doi:10.3390/ijms21155330. PMID: 32727084. Polati E, Martini A, Schweiger V. Ultramicronized palmitoylethanolamide treatment in central neuropathic pain following longstanding spinal cord injury: try to extinguish the fire after everything was burned. Pain. 2017;158(4):763-764. PMID: 28301405. About Dr. Kim Yoon Hang Kim, MD, MPH is a board-certified physician with more than 20 years of clinical experience. He completed a fellowship at the University of Arizona under Dr. Andrew Weil and holds board certification in Preventive Medicine along with certifications in medical acupuncture and integrative and holistic medicine. His clinical focus includes low dose naltrexone (LDN), autoimmune conditions, chronic pain, integrative oncology, fibromyalgia, chronic fatigue syndrome, mast cell activation syndrome (MCAS), and mold toxicity. He is the author of four books and more than 20 peer-reviewed articles, including MCAS: Epidemic in Plain Sight and LDN Primer, both available on Amazon. He is also the founder of the LDN Support Group. Yoon Hang Kim, MD, MPH | Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician Professional: www.yoonhangkim.com | Clinical: www.directintegrativecare.com

Association Is Not Causation Looking Deeper into the Melatonin–Heart Failure Study Yoon Hang Kim, MD, MPH Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician Meet Yoon Hang Kim MD Important: This article is intended for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment. Always consult your physician or qualified healthcare provider before making changes to your supplement regimen. The Headline vs. the Evidence If you follow health news, you may have seen some alarming headlines recently: "Melatonin linked to heart failure." For many of my clients — people who rely on melatonin as a safe, non-habit-forming sleep aid — this kind of headline is genuinely unsettling. But as is so often the case, what the study actually found and what the headline implies are two very different things. Let's walk through what this research really showed, where its limitations lie, and what it means for you practically. What the Study Actually Found The analysis in question was a retrospective electronic health record (EHR) cohort study presented as an abstract at an American Heart Association (AHA) scientific session. The researchers used a large database called TriNetX to compare people who had documented long-term melatonin use against those who did not. After propensity-score matching — a statistical technique designed to make the two groups more comparable on recorded characteristics — they found that the melatonin group had a higher incidence of heart failure over five years: roughly 5% versus 3%, with a hazard ratio of 1.89. That is a real statistical association. It is not evidence that melatonin caused heart failure. The distinction matters enormously — and it is the single most important thing to understand about this study. Why Association Is Not Causation In epidemiology, we learn early that observing two things happening together does not tell us that one caused the other. The classic example: ice cream sales and drowning rates both rise in summer. Ice cream does not cause drowning. A shared factor — warm weather — drives both. This same logic applies here. Propensity matching can adjust for measured variables: age, sex, comorbidities, medications, lab values, and healthcare utilization patterns. That is valuable, and to the researchers' credit, the association persisted even under a stricter prescription-fill definition. But matching cannot account for what it cannot see. The Confounders Hiding in Plain Sight The most significant concern is what epidemiologists call confounding by indication — the idea that the very reason someone takes melatonin long-term may itself be the thing that raises their heart failure risk. Think about who uses melatonin chronically. These are often people dealing with: Severe, treatment-resistant insomnia Anxiety or depression Chronic pain syndromes Shift-work schedules that disrupt circadian rhythm Undiagnosed or undertreated sleep apnea Neurocognitive conditions General frailty or aging-related sleep disruption Every single one of these conditions is independently associated with cardiovascular risk. If the melatonin group was enriched for these burdens — and it almost certainly was, because those are the reasons people take melatonin long-term — then the heart failure signal may reflect the underlying conditions, not the supplement. Other Limitations Worth Knowing Exposure misclassification. Melatonin is available over the counter. Many people in the "non-user" group may have been taking it — they just never told their doctor. The study could not capture dose, formulation, timing, or adherence with any precision. When you cannot clearly define who is actually exposed and who is not, your results become unreliable. Reverse causation. Heart failure does not appear overnight. In its early, undiagnosed stages, it can cause fluid retention, nocturnal dyspnea, and disrupted sleep — all of which might lead someone to start taking melatonin. In that case, melatonin use would be a marker of evolving heart disease rather than a cause of it. Outcome validity. The heart failure "outcome" was an ICD billing code in an EHR. These codes are used for administrative purposes and are not the same as independently verified, clinician-adjudicated diagnoses. The particularly striking difference in heart failure hospitalizations between groups raises questions about whether the groups had different baseline vulnerabilities or different patterns of healthcare contact. Abstract-level evidence. This was a conference presentation, not a published peer-reviewed manuscript. The full methods, covariate definitions, missing-data handling, and subgroup analyses have not yet been subjected to formal peer scrutiny. What Would It Take to Prove Causation? If researchers want to move beyond association, the next logical step would be a well-designed prospective cohort study: enroll people when they first start melatonin, compare them to clinically similar people starting a different sleep strategy, measure dose and adherence carefully, account for sleep apnea and insomnia severity, and follow them forward with independently verified heart failure outcomes. The gold standard would be a randomized controlled trial — melatonin versus placebo in a defined insomnia population, with blinded, adjudicated outcomes. Randomization handles both measured and unmeasured confounding. But heart failure events are uncommon enough that such a trial would need to be very large and very long, making it expensive and logistically challenging. Until that work is done, this study gives us a safety signal. It does not give us a conclusion. What This Means for You If you are my client and you take melatonin, this study is not a reason to panic. But it is a reasonable prompt to reflect on a few things: Why are you taking it? If the answer is "I've been taking it for years and never questioned it," that deserves a conversation. Chronic supplement use without periodic reassessment is common, and it is worth revisiting the rationale. Have underlying sleep issues been addressed? If melatonin is masking untreated sleep apnea, anxiety, or circadian disruption, the right move is to address the root cause — not simply add a nightly supplement indefinitely. Dose and duration matter. Most over-the-counter melatonin is dosed far higher than what the body produces physiologically. Working with a knowledgeable clinician to find the lowest effective dose — or to explore whether you still need it at all — is prudent. Melatonin remains, by the available evidence, one of the safest sleep-supporting supplements. This study does not change that conclusion — but it does remind us that no supplement should be taken on autopilot forever. The Right Question to Ask A good way to think critically about studies like this is to ask: What characteristic could lead someone to use melatonin long-term AND independently raise their risk of heart failure — even after the statistical adjustments? If you can think of even one plausible answer (and we listed several above), then you have identified a reason to be cautious about drawing causal conclusions from this data. Headlines are designed to get clicks. Your health decisions deserve more nuance than a headline can offer. About Dr. Kim Yoon Hang Kim, MD, MPH, is board-certified in Preventive Medicine with over 20 years of experience in integrative and functional medicine. A graduate of the University of Arizona Center for Integrative Medicine's prestigious Osher Fellowship under Dr. Andrew Weil, Dr. Kim holds certifications in preventive medicine, medical acupuncture, and integrative and functional medicine. He specializes in low-dose naltrexone (LDN), autoimmune conditions, chronic pain, integrative oncology, fibromyalgia, chronic fatigue syndrome, mast cell activation syndrome (MCAS), and mold-related illness. Dr. Kim is the author of MCAS: Epidemic in Plain Sight and LDN Primer, both available on Amazon, and the founder of the LDN Support Group. He has published over 20 peer-reviewed articles and authored multiple clinical texts on integrative approaches. Professional: www.yoonhangkim.com | Clinical: www.directintegrativecare.com

By Yoon Hang "John" Kim, MD, MPH — Board-Certified Preventive Medicine Physician specializing in Integrative and Functional Medicine | www.directintegrativecare.com Abstract Creatine monohydrate is one of the most extensively studied dietary supplements available, with over three decades of clinical trial data supporting its role in improving strength, lean mass, and high-intensity exercise capacity. Despite this, confusion between creatine (the supplement) and creatinine (its metabolic waste product) continues to cause unnecessary alarm when routine kidney labs come back looking “off.” This article explains the difference between the two molecules, reviews what the evidence — including 2025–2026 meta-analyses — actually supports regarding muscle performance, cognitive function, and kidney safety, and offers practical guidance on dosing, product selection, and when to involve your physician. Recent data confirm that creatine supplementation modestly raises serum creatinine (approximately 0.13–0.14 mg/dL on average) without corresponding changes in directly measured kidney filtration, reinforcing that this is a lab artifact rather than evidence of kidney injury in healthy individuals. The goal is simple: help you understand what creatine does, what it does not do, and how to have a smarter conversation with your clinician about what your labs actually mean. Patients ask about creatine more often now than they did five years ago. It used to live almost entirely in the gym conversation. It now shows up in conversations about aging muscle, brain fog after poor sleep, plant-based diets, and "my creatinine came back high and my doctor is worried." That last sentence is why this article exists. Creatine and creatinine sound like the same molecule with a typo. They are not. Confusing them leads people to stop a useful supplement — or, worse, to ignore a real kidney problem because "it's just the creatine." Both mistakes are avoidable. This is educational, not a prescription. If you have kidney disease, take medications that affect the kidneys, or you are pregnant or breastfeeding, talk with your own clinician before you start anything. Creatine and Creatinine Are Related — They Are Not Interchangeable Creatine is a compound your body makes from three amino acids: arginine, glycine, and methionine. About 95% of body creatine is stored in skeletal muscle, with roughly two-thirds present as phosphocreatine. When you need a fast burst of energy — a heavy lift, a sprint, standing up quickly as you get older — phosphocreatine donates a phosphate group to regenerate ATP. Your liver, kidneys, and pancreas make about 1 gram a day. A typical omnivorous diet adds another 1–2 grams from meat and fish. Muscle stores sit about 60–80% full on diet alone. Supplementation can raise those stores another 20–40%. Creatinine is the waste product. Every day, roughly 1–2% of your muscle creatine pool spontaneously breaks down into creatinine. The kidneys filter it. That is why serum creatinine (and the eGFR calculated from it) became a routine kidney marker. A simple way to remember it: Creatine is the fuel. Creatinine is the exhaust. More fuel in the tank means a little more exhaust. That does not automatically mean the engine is failing. What the Evidence Actually Supports Creatine monohydrate is one of the most studied dietary supplements we have — hundreds of trials over three decades. The International Society of Sports Nutrition has called it the most effective ergogenic nutritional supplement currently available for increasing high-intensity exercise capacity and lean mass during training. What holds up Strength and lean mass when you train. Combined with resistance training, creatine reliably improves strength and adds lean mass — often around 1 kg of additional lean mass on average, with larger gains in some studies — over 8–12 weeks in study settings. It does not replace training. It helps you do a little more work in the sessions you already do. Aging muscle (sarcopenia). We lose muscle with age. That loss is not cosmetic. It affects balance, blood sugar handling, recovery from illness, and independence. Creatine plus protein plus actual strength work is one of the more practical stacks we have for older adults. People who eat little or no animal protein. Vegetarians and vegans start with lower muscle creatine stores. They frequently see substantial increases in tissue creatine after supplementation, although evidence that their performance response is always greater than omnivores is mixed. In practice, many notice a real difference. Brain energy under stress. The brain uses creatine too. The performance data is strongest for muscle. The cognitive data is newer and smaller, but directionally interesting: a 2024 meta-analysis found modest benefits for memory and some processing measures, particularly under sleep deprivation or metabolic stress. Preliminary adjunctive research in depression exists, but the clinical benefit remains very uncertain. I treat the cognitive angle as promising, not settled. Postmenopausal women. A 2026 meta-analysis found a small increase in lean mass (roughly 0.37 kg) and improved leg-press strength when creatine — especially at doses of 5 grams per day or more — accompanied resistance training. Bone-density benefit was not demonstrated overall, but the muscle and strength conversation overlaps meaningfully with the bone conversation in this population. Evidence is growing, not finished. What does not hold up Creatine is not a steroid. Creatine is not a fat-gain drug. Early scale weight is mostly intramuscular water. Fancy forms (ethyl ester, "buffered," many patented variants) have not beaten plain creatine monohydrate in head-to-head work. Some — creatine ethyl ester in particular — convert to creatinine faster and actually perform worse. Pay for purity and third-party testing, not for a new molecule name. Does Creatine Damage the Kidneys? In healthy people, at usual doses, the best available evidence says no. What creatine does do is raise the lab number we use as a kidney proxy. Creatine can modestly increase serum creatinine because more creatine is available for conversion to creatinine. Recent meta-analyses — including two published in 2026 — found an average serum creatinine increase of about 0.13–0.14 mg/dL. Creatinine-based eGFR may therefore appear lower even when true kidney filtration has not changed. Crucially, when researchers measured filtration directly using creatinine-independent methods (such as Cr-EDTA clearance), they found no change. That strongly suggests a measurement artifact, not nephron injury. Side-effect rates in pooled trial data look similar to placebo; the most common complaints are gastrointestinal discomfort if the dose is dumped in all at once. One nuance worth noting: long-term randomized data beyond approximately one year are much thinner than the short- and medium-term evidence. So I will not say renal safety has been proved indefinitely in every population. What I will say is that the current evidence, across a large number of studies, has not shown a signal of kidney damage in healthy adults using recommended doses. The caveat is real and I do not wave it away: Known chronic kidney disease eGFR already reduced Nephrotoxic medications Unexplained rising creatinine before anyone started creatine Pregnancy and lactation (not enough safety data) Those are "talk to your physician first" situations, not internet-protocol situations. If you are already on creatine and a routine panel looks worse, tell the person reading the labs. Ask whether cystatin C — a kidney marker that is not generated from creatine metabolism and is less dependent on muscle mass — would clarify the picture. Combining creatinine and cystatin C can sometimes give a more informative estimate than relying on creatinine alone. Temporarily stopping creatine and repeating testing after an appropriate interval can also sometimes clarify the picture. How I Think About Dosing in Practice There are two honest ways to saturate muscle stores. Daily low dose (what most people should do): 3–5 grams of creatine monohydrate every day. Saturation takes three to four weeks. Fewer GI issues. No drama. Optional loading: About 20 grams a day, split into 4 doses of roughly 5 grams each, for 5–7 days, then 3–5 grams daily. Faster saturation. More water retention and more GI complaints. Not required. I generally skip loading unless someone has a time-sensitive training block and tolerates split doses. Consistency beats cleverness. Practical notes that matter more than timing debates Take it with food if your stomach is sensitive. Maintain normal hydration. Creatine can increase intracellular water, especially early in supplementation, but controlled studies do not show that it causes dehydration. Powder is cheaper and fine. Capsules are convenience, not magic. Look for creatine monohydrate, ideally Creapure or another batch that is third-party tested (NSF, Informed Sport, USP). The risk in this category is usually a dirty product, not the molecule. You do not need to "cycle" it if you are healthy and the dose is ordinary. Who Is a Reasonable Candidate — and Who Is Not Reasonable to discuss: People who lift or do repeated high-intensity work Adults over 50 trying to keep muscle Vegetarians and vegans Patients whose fatigue picture includes low training capacity and who already have a training plan Some women in peri- and postmenopause, where muscle and bone conversations overlap Pause and get medical input first: Established kidney disease Unexplained abnormal creatinine or eGFR Heart failure with tight fluid management Adolescents should not self-experiment; use should occur with appropriate parental and professional supervision. The ISSN considers supervised use acceptable in appropriately trained young athletes, but that is different from a teenager ordering it online. Pregnancy and breastfeeding — human supplementation safety data remain insufficient to recommend routine use Creatine is not a treatment for fibromyalgia, MCAS, autoimmune disease, or cancer. In my practice those conditions have their own frameworks. If someone in that group also wants to protect muscle while they train, we talk about labs, hydration, and the creatinine-lab artifact before they start — not after a panicked portal message. How This Fits a Functional Medicine Visit A supplement is never the first question I ask. The first questions are still the boring ones that change outcomes: protein intake, resistance training two or three days a week, sleep, hydration, and whether the person can actually recover from the work they are doing. If those pieces are in place, creatine monohydrate is one of the few supplements with a risk-benefit ratio I am comfortable discussing in clinic. If those pieces are missing, creatine will not rescue the plan. If you are a patient of Yoon Hang Kim MD and you start creatine, put it on your supplement list and tell me before the next lab draw. That single sentence prevents a lot of unnecessary alarm. Frequently Asked Questions About Creatine Is creatinine a supplement? No. Creatinine is a waste product. The supplement is creatine. Will creatine make my creatinine high? It can raise the number modestly. That is not the same as kidney failure. Context and, when needed, a second marker like cystatin C matter. What form of creatine should I buy? Creatine monohydrate. Micronized dissolves more easily. Everything else needs a better reason than marketing. Do I need a loading phase? No. Helpful if you want saturation in a week. Unnecessary if you can wait a month. Can I take creatine with LDN or other medications? No specific interaction between creatine and low-dose naltrexone has been established in the published literature, although formal interaction data are limited. The practical issue is the creatinine lab, not a drug-drug clash. Medication lists still belong in the conversation with your prescriber. Does creatine cause hair loss? An older small study raised concern about a DHT shift in a group of rugby players. However, a 2025 randomized trial measured DHT and actual hair-follicle and hair-density outcomes after 12 weeks of 5 grams per day of creatine and found no significant differences from placebo. Current evidence does not support creatine causing hair loss. Summary What creatine is: A naturally occurring compound stored primarily in skeletal muscle that helps regenerate ATP during short, high-intensity efforts. Your body makes about 1 gram per day; diet adds 1–2 grams; supplementation can raise muscle stores by 20–40%. What the evidence supports: Creatine monohydrate, at 3–5 grams daily, reliably improves strength and lean mass when combined with resistance training. Benefits extend to older adults fighting sarcopenia, vegetarians and vegans with lower baseline stores, and postmenopausal women. Cognitive benefits under metabolic stress are promising but not yet settled. What it does to your labs: Creatine raises serum creatinine by roughly 0.13–0.14 mg/dL on average, which can make eGFR look lower. Two 2026 meta-analyses confirmed this is a measurement artifact — directly measured kidney filtration does not change. This is not kidney damage. It is more exhaust from a fuller tank. What it does not do: It is not a steroid. It does not cause dehydration. It does not cause hair loss (a 2025 randomized trial found no effect on DHT or hair density). Fancy branded forms have not outperformed plain creatine monohydrate. Who should pause: Anyone with established kidney disease, unexplained abnormal creatinine, heart failure with tight fluid management, unsupervised adolescents, or women who are pregnant or breastfeeding should get medical guidance before starting. The bottom line: Creatine monohydrate is one of the best-supported, lowest-risk, and least expensive supplements available for healthy adults who train. If your creatinine rose after you started it, do not panic and do not ignore it. Bring the bottle, the dose, and the timeline to the clinician who ordered the labs. That conversation is the whole point. The Honest Bottom Line Creatine monohydrate is not a miracle, and it is not a menace. For healthy adults who train, eat enough protein, and understand what their labs mean, it is one of the better-supported, inexpensive tools we have for muscle and high-intensity work. For people with real kidney disease, it is a medical decision, not a cart-checkout decision. If your creatinine rose after you started creatine, do not panic and do not ignore it. Bring the bottle, the dose, and the timeline to the clinician who ordered the labs. If you want help sorting whether creatine belongs in your plan — next to the rest of your history, medications, and labs — that is the kind of conversation we have at Yoon Hang Kim MD. ——— Yoon Hang "John" Kim, MD, MPH, FAAMA, is a board-certified preventive medicine physician specializing in integrative and functional medicine. He is an IFM Scholar, a graduate of the University of Arizona Integrative Medicine Fellowship under Dr. Andrew Weil, and provides telemedicine care through Yoon Hang Kim MD to patients in Iowa, Illinois, Missouri, Georgia, Florida, and Texas. This article is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting or changing any supplement or treatment.

By Yoon Hang Kim, MD, MPH Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician Low dose naltrexone (LDN) is often discussed as though there is one standard dose, one predictable response, and one straightforward way to use it. In clinical practice, it is rarely that simple. People differ dramatically in sensitivity, diagnosis, immune function, nervous system reactivity, medication tolerance, and response to dose changes. This becomes especially important in patients with mast cell activation syndrome (MCAS), multiple chemical sensitivity, chronic pain, neuropathy, autoimmune disease, and complex chronic illness. During a recent LDN Support Group live session, I answered questions about some of the most common challenges people encounter with LDN. What follows are the key teaching points from that conversation. LDN and Neuropathic Pain One question involved using LDN for an "overactive nerve" that flares easily. Without knowing the underlying diagnosis, it is difficult to say exactly what is being treated. However, when we are talking about neuropathic pain, LDN may be working through mechanisms beyond simply blocking opioid receptors and increasing endogenous endorphins. One proposed mechanism involves Toll-like receptor 4 (TLR4), which is associated with glial-cell activation and neuroinflammation. When TLR4 is activated on microglia — the most prevalent immune cells of the nervous system — it can trigger a cascade of proinflammatory cytokines including interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α). LDN appears to act as a TLR4 antagonist, competitively binding to the receptor and blocking downstream inflammatory signaling (Parkitny & Younger, 2017; Toljan & Vrooman, 2018). This mechanism is particularly interesting when we think about neuropathic pain. I experienced this personally after surgery. I developed significant nerve pain and was prescribed opioids and gabapentin. The gabapentin affected me so strongly that I could barely walk safely and needed two canes. I ultimately used naltrexone along with non-opioid pain strategies, and it made a major difference for me. One important point is that dosing for neuropathic pain may not necessarily be identical to dosing used for autoimmune or other conditions. The diagnosis matters. Related reading: LDN, Emotional Distress, Neuropathy, Chronic Fatigue Syndrome, and Mitochondrial Support What If LDN Causes Headache or Nausea? Another person described starting at 0.25 mg, increasing to 0.5 mg after two weeks, and eventually reaching 0.75 mg. They subsequently developed persistent headaches and nausea. When symptoms appear after increasing LDN, I generally do not recommend simply pushing through them. My usual clinical approach is to back off. That may mean stopping the medication temporarily, allowing symptoms to settle, and — if LDN is restarted — returning at a much lower dose and titrating much more slowly. I sometimes describe this pattern as being consistent with an inadequate endorphin response or "endorphin deficiency" relative to the degree of opioid receptor blockade. Whatever terminology we use, the practical message is the same: if the dose is making you significantly worse, more is not necessarily better. Related reading: The Endorphin Depletion Hypothesis in CFS/ME LDN, Vivid Dreams, and Insomnia Sleep disruption is one of the more commonly reported challenges with LDN. People may experience vivid dreams, difficulty falling asleep, or severe insomnia. When someone tells me they are taking a "low dose," however, I usually ask: What dose? The phrase "low dose" is not precise enough. For one person, 4.5 mg may be considered low dose. For another person, 0.25 mg may be far too much. A highly sensitive patient may need to begin in the microgram range. Rather than saying, "I'm taking a low dose," tell your clinician: "I'm taking 0.5 mg." That makes the conversation much more useful. When insomnia becomes severe after starting or increasing LDN, I consider the possibility that the dose is simply too high for that individual. Stopping and restarting much lower may be more productive than continuing to increase. Related reading: LDN in Functional Medicine: A Practical Guide Can Symptoms Get Worse After Increasing LDN? Yes. A person may improve at one dose and then worsen after increasing it. That may look paradoxical, but biological systems do not always follow a simple linear dose-response curve. More medication does not automatically mean more benefit. This is why I believe patients should participate actively in determining their LDN dosing strategy. You are the person experiencing the medication every day. Pay attention. Keep notes. Watch what happens to your sleep, pain, energy, gastrointestinal symptoms, mood, cognition, and other symptoms as the dose changes. Individual observation can be extremely valuable. Blood in the Stool Is Not an LDN Question One participant described a 19-year-old with MCAS who was taking LDN. Energy had improved, but severe insomnia persisted. The person also had chronic diarrhea and blood in the stool. At that point, the most important issue is not adjusting LDN. Blood in the stool requires appropriate medical evaluation. Inflammatory bowel disease is one possibility, and LDN has historically been studied in inflammatory bowel disease, including pediatric populations (Smith et al., 2013). But LDN should not become a substitute for establishing the diagnosis. If there is persistent diarrhea, bleeding, or another concerning symptom, seek appropriate medical evaluation. Treating presumed disease without first evaluating serious possibilities can be dangerous. Can LDN Help Autoimmune Disease? Another question came from someone with multiple autoimmune or inflammatory conditions, including Hashimoto's thyroiditis, lichen-related disease, and psoriasis. I have seen patients with autoimmune disorders benefit from LDN. A 2019 Norwegian registry study found that persistent LDN users with rheumatoid arthritis showed a 13% relative reduction in dispensing of all rheumatic medications and a 23% reduction in analgesic use (Raknes & Småbrekke, 2019). But I would strongly caution against thinking, "LDN must fix this." Responses are highly individual. LDN may help modulate inflammation or symptoms, but it should not automatically be viewed as a cure or as an emergency medication designed to extinguish every inflammatory process. Sometimes conventional medicine is exactly what is needed to "put out the fire." LDN may then serve as one component of a larger strategy. MCAS Patients May Need Extremely Small Doses One person with MCAS told their physician they were highly medication-sensitive and wanted to start with a microdose. They were started at 1 mg. For some patients with MCAS, 1 mg can be an enormous starting dose. In my own practice, particularly sensitive MCAS patients may begin around the microgram range. One milligram equals 1,000 micrograms. That difference matters. Highly sensitive patients should not necessarily be treated using the same titration schedule as the average patient. MCAS changes the equation. Related reading: MCAS: A New Epidemic in Plain Sight MCAS Diagnosis Requires Flexible Thinking MCAS can also be challenging because laboratory testing is imperfect. There are diagnostic criteria and laboratory protocols, but no single test perfectly identifies every patient with mast cell activation. Timing also matters. Histamine and related mediators may be transient, and some testing is most informative when performed during active symptoms. Twenty-four-hour metabolite testing may sometimes help, but even that is not perfect. Because we do not have a single test with perfect sensitivity, clinical reasoning remains important. We should consider symptoms, history, response patterns, laboratory information, and alternative diagnoses together. Rigid thinking can cause clinicians to miss patients whose presentation does not fit neatly into one laboratory box. Related reading: The COMT Gene and Mast Cell Activation Syndrome: Mechanistic Links, Clinical Implications, and the Limits of Current Evidence LDN Is Usually Not Emergency Treatment for MCAS One of the biggest misconceptions I see is the expectation that long-term immune-modulating therapy should behave like emergency treatment. People frequently come to me when they are desperate. Understandably, they want something that works immediately. Sometimes a patient does experience rapid improvement. But for many patients with MCAS, treatment requires weeks or months. The strategy may involve introducing one intervention, evaluating tolerance, titrating carefully, and then deciding whether another intervention should be added. That process cannot always be rushed. Even medications such as omalizumab (Xolair) may require months before clinicians can properly judge the response. Immune modulation takes time. Related reading: Lactobacillus rhamnosus GG (LGG) in Mast Cell Activation Syndrome When You Have Multiple Diagnoses, Fight One Dragon at a Time Another participant had a combination of chronic pain, autoimmune disease, fibromyalgia, occipital neuralgia, Hashimoto's disease, anxiety, and possibly polymyalgia rheumatica. These are not simple cases. When someone has many overlapping diagnoses, I often use the analogy of being surrounded by dragons. LDN is one weapon. Trying to fight every dragon simultaneously with the same weapon usually creates confusion. Instead, decide which dragon matters most. What is the primary problem? What condition is driving the greatest disability? What needs urgent conventional treatment? What problem can reasonably be addressed next? In complex patients, I often prefer to address one major target at a time rather than changing five medications and ten supplements simultaneously. Otherwise, when something improves — or worsens — you may have no idea why. If You Are Feeling Better, What Should You Stop First? Someone asked what to reduce when they are doing well but taking LDN, ketotifen, exogenous ketones, and a large number of supplements. This is another situation where individualized medical guidance helps. In my practice, I generally do not start by removing necessary prescription medication. I am more likely to first examine the supplement list. Does every supplement still have a purpose? Was it originally prescribed for a problem that has now resolved? Are multiple products duplicating ingredients? Can the regimen be simplified? Exogenous ketones are another area worth examining. Your body can make ketones through nutritional ketosis. Exogenous ketones may have specific uses, but they are not automatically necessary simply because someone benefits from ketosis. Simplification should be thoughtful, deliberate, and preferably performed one change at a time. Sublingual and Topical LDN Questions also come up about sublingual and topical LDN. Based on discussions I have had with compounding pharmacists, these routes may sometimes produce inconsistent results. One potential issue is the carrier and how effectively the medication reaches systemic circulation. Transdermal delivery in particular depends heavily on formulation. Although I may think experimentally about different carriers, I am not a compounding pharmacist, and formulation decisions should ultimately be made with someone who understands pharmaceutical compounding. Route of administration matters just as much as the number printed on the bottle. "It Was Working Until I Increased the Dose" Another participant had done very well at 3.5 mg but developed worsening pain after increasing to 4 mg. They then reduced to 3 mg after a 24-hour break. This is a common lesson with LDN: if 3.5 mg works, you do not necessarily need 4 mg. There is no prize for reaching the highest dose. The goal is to identify the dose that produces the best overall response. For some people, a 24-hour break may also be too short after developing a significant adverse reaction. In particularly sensitive patients, allowing more time for the system to settle may be reasonable before deciding what to do next. What Does "Microdose" Actually Mean? Terminology around LDN has become confusing. People sometimes describe 1 or 2 mg as a "microdose." Technically, however, a microgram dose is very different from a milligram dose. For example: 1 mg = 1,000 micrograms. 2 mg = 2,000 micrograms. When discussing LDN, I encourage people to stop relying on vague terms such as "low dose," "very low dose," "ultra-low dose," or "microdose." Instead, simply state the actual dose. The number provides much more useful clinical information. The published literature distinguishes these ranges more precisely. Toljan and Vrooman (2018) define LDN as 1–5 mg/day, very low-dose naltrexone (VLDN) as 1 µg–1 mg, and ultra-low-dose naltrexone (ULDN) as less than 1 µg/day. These distinctions carry different pharmacodynamic implications. Chronic Fatigue Requires a Differential Diagnosis We also discussed testing for chronic fatigue. There is considerable interest in newer biomarkers and specialized tests. Those tests can be useful. But chronic fatigue should still trigger a broader medical evaluation. The differential diagnosis may include sleep disorders, endocrine abnormalities, nutritional deficiencies, infections, autoimmune disease, hormonal problems, and other medical conditions. Performing one specialized test while ignoring the major differential diagnoses is not comprehensive medicine. A better approach is to systematically evaluate the common and important possibilities while integrating newer testing when appropriate. Related reading: The Endorphin Depletion Hypothesis in CFS/ME Rotate Sleep Tools Rather Than Depending on One Thing Forever A final question involved supplements for sleep and mood. One general strategy I use is to avoid relying on the same sleep intervention every night whenever possible. If one intervention works, perhaps use it selectively. Find another strategy that also works. And another. The goal is to develop a toolbox. For example, someone might rotate among several appropriate strategies rather than repeatedly depending on one intervention until its effectiveness diminishes. Sleep is complex, and sometimes having several tools is more sustainable than looking for one perfect solution. The Bigger Lesson: LDN Is Highly Individualized LDN can be remarkably useful. I have seen it help with neuropathic pain, autoimmune conditions, inflammatory disorders, and complex chronic illness. I have also seen people develop insomnia, nausea, headaches, worsening symptoms, or paradoxical reactions when the dose is wrong for them. The lesson is not that LDN is good or bad. The lesson is that LDN is individualized. The right question is often not, "What is the correct LDN dose?" It is: "What is the correct LDN dose for this particular person, for this particular condition, at this particular point in time?" Start thoughtfully. Pay attention to your response. Do not assume that increasing the dose will increase the benefit. And when dealing with MCAS or highly medication-sensitive patients, remember that sometimes the difference between success and failure is simply starting much, much lower. References Parkitny L, Younger J. Reduced pro-inflammatory cytokines after eight weeks of low-dose naltrexone for fibromyalgia. Biomedicines. 2017;5(2):16. doi:10.3390/biomedicines5020016 Toljan K, Vrooman B. Low-dose naltrexone (LDN) — review of therapeutic utilization. Medical Sciences. 2018;6(4):82. doi:10.3390/medsci6040082 Raknes G, Småbrekke L. Low dose naltrexone: effects on medication in rheumatoid and seropositive arthritis. A nationwide register-based controlled quasi-experimental before-after study. PLoS One. 2019;14(2):e0212460. doi:10.1371/journal.pone.0212460 Smith JP, Stock H, Bingaman S, Mauger D, Rogosnitzky M, Zagon IS. Low-dose naltrexone therapy improves active Crohn's disease. Am J Gastroenterol. 2007;102(4):820-828. doi:10.1111/j.1572-0241.2007.01045.x Smith JP, Bingaman SI, Ruber F, et al. Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn's disease: a randomized placebo-controlled trial. Dig Dis Sci. 2011;56(7):2088-2097. doi:10.1007/s10620-011-1653-7 Pogue J, Johnson D, Burch A. A utilization review of patients that respond to low-dose naltrexone (LDN) for chronic pain. J Pain Res. 2023;16:1993-1998. doi:10.2147/JPR.S389957 McKenzie-Brown AM, Boorman DW, Ibanez KR, et al. Real world effectiveness and tolerability of low dose naltrexone to treat chronic pain. J Pain Res. 2024;17:1273-1284. doi:10.2147/JPR.S451183 Younger J, Noor N, McCue R, Mackey S. Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels. Arthritis Rheum. 2013;65(2):529-538. doi:10.1002/art.37734 More from IFMSynergy LDN in Functional Medicine: A Practical Guide LDN, Emotional Distress, Neuropathy, Chronic Fatigue Syndrome, and Mitochondrial Support The Endorphin Depletion Hypothesis in CFS/ME MCAS: A New Epidemic in Plain Sight The COMT Gene and MCAS: Mechanistic Links and Clinical Implications Lactobacillus rhamnosus GG (LGG) in MCAS Medical Disclaimer: This article is for educational and informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare professional before starting any new treatment, supplement, or medication. Individual responses to therapies vary, and the information presented here should not replace the clinical judgment of your physician. Yoon Hang Kim, MD, MPH LDN Support Group | www.ldnsupportgroup.org IFMSynergy | www.ifmsynergy.com

By Yoon Hang "John" Kim, MD, MPH I can't tell you how many patients walk into my office already taking melatonin — sometimes way more than they need — and still not sleeping. They're frustrated. They did the "natural" thing. It didn't work. Now what? That's usually when I bring up saffron, and I get the look. The cooking spice? Sort of. We're not talking about pinching threads into your rice. We're talking about a concentrated, standardized extract that's been put through legitimate clinical trials. And honestly, the data surprised me when I first dug into it. What does the research actually show? Multiple randomized, controlled trials have studied saffron extract for sleep — real studies with placebo groups and measurable outcomes. The results have been consistent: participants who took standardized saffron extract before bed reported meaningful improvements in sleep quality, fell asleep faster, and slept longer. Several studies also showed that saffron increased the body's own evening melatonin production — without taking melatonin from the outside.[1,2,3] Most people notice a shift within three to four weeks of consistent use. This isn't something that knocks you out on night one. It builds. For specific dosing guidance and a deeper dive into the clinical evidence, visit my academic blog at www.ifmsynergy.com. A few things worth knowing Get the right product. The extract studied most is called Affron®. It's standardized to the active compounds — crocins and safranal. The saffron in your spice cabinet won't cut it. Be patient. Four weeks minimum. Some trials ran eight weeks. This is a slow burn, not a sedative. Talk to your doctor. Saffron can amplify sedative medications, and it should be avoided during pregnancy. At the doses used in clinical research, it has an excellent safety profile — but it's always worth a conversation with your provider.[10] Two supplements, two completely different jobs People lump melatonin and saffron together as "natural sleep aids," but they're doing fundamentally different things in your body. Melatonin is a hormone. When you swallow it, you're adding it from the outside. It talks to the receptors in your brain that set your internal clock, which makes it genuinely useful when the timing of your sleep is the problem — jet lag, night shifts, a body clock that runs two hours late. Saffron works on a different level entirely. It supports the brain pathways that calm you down — the same ones tangled up in stress and anxiety. And here's the part that really caught my attention as a clinician: saffron doesn't replace your melatonin. It nudges your body into making more of its own.[2] That matters. There's growing concern that taking melatonin from the outside — especially at the high doses people tend to use — can dial down your body's natural production over time. Saffron seems to push things in the other direction. How do they compare in the research? When you put the trial outcomes next to each other, the difference is hard to ignore — at least for the kind of sleep trouble most people deal with. In studies of people with chronic, stress-related insomnia, saffron consistently produced larger improvements in how fast people fell asleep, how long they stayed asleep, and how efficient their sleep was overall. Melatonin, by contrast, showed more modest results for primary insomnia — but strong results for circadian-related issues like jet lag and shift work.[1,2,7] For the lying-awake-at-2am-with-your-brain-on-fire kind of insomnia, saffron has the stronger evidence. But if your issue is that your body doesn't know what time zone it's in, melatonin is still the right call. For a detailed comparison of the clinical outcomes, visit www.ifmsynergy.com. How I think about it in practice My framework is simple. I lean toward saffron when someone's sleep trouble comes packaged with stress, worry, or a mind that won't stop running. That's the majority of my clients. Saffron is safe for longer-term use, supports the body's own chemistry, and the trial data backs it up. I lean toward melatonin when the core issue is timing. Jet lag. Rotating shifts. A teenager whose body clock thinks midnight is 10 PM. Sometimes I use both. They're not competing; they're working on different systems. Where this leaves us Saffron isn't going to fix everything. No supplement will. If your sleep hygiene is a mess, if you haven't been screened for sleep apnea, if you're doom-scrolling until midnight and wondering why you can't fall asleep — we need to address that first. But as one piece of a bigger plan? Standardized saffron extract is one of the better-supported natural options available right now for chronic, stress-driven insomnia. The research is real. The safety margin is wide. And in my experience, clients who try it tend to stick with it — which tells me something. If melatonin hasn't been doing the job, it might be time for a different conversation. Dr. Kim is board-certified in Preventive Medicine and practices integrative & functional medicine. He is the author of MCAS: Epidemic in Plain Sight and LDN Primer, both available on Amazon. He is also the founder of the LDN Support Group. References Lopresti AL, Smith SJ, Metse AP, Drummond PD. Effects of saffron on sleep quality in healthy adults with self-reported poor sleep: a randomized, double-blind, placebo-controlled trial. J Clin Sleep Med. 2020;16(6):937–947. Lopresti AL, Smith SJ, Drummond PD. An investigation into an evening intake of a saffron extract (affron®) on sleep quality, cortisol, and melatonin concentrations in adults with poor sleep: a randomised, double-blind, placebo-controlled, multi-dose study. Sleep Med. 2021;86:7–18. Pachikian BD, Copine S, Suchareau M, Deldicque L. Effects of saffron extract on sleep quality: a randomized double-blind controlled clinical trial. Nutrients. 2021;13(5):1473. Schuster J, Mundhenke C, Nordsieck H, Pouchieu C, Pourtau L, Hahn A. Effect of a saffron extract on sleep quality in adults with moderate insomnia: a decentralized, randomized, double-blind, placebo-controlled trial. Sleep Medicine: X. 2025;10:100147. Lian Y, Yin F, Yang C, et al. Effects of saffron supplementation on improving sleep quality: a meta-analysis of randomized controlled trials. Sleep Med. 2022;92:24–33. Rafiei SKS, Abolghasemi S, Frashidi M, et al. Saffron and sleep quality: a systematic review of randomized controlled trials. Nutr Metab Insights. 2023;16:11786388231160317. Ferracioli-Oda E, Qawasmi A, Bloch MH. Meta-analysis: melatonin for the treatment of primary sleep disorders. PLoS One. 2013;8(5):e63773. Bruni O, Ferini-Strambi L, Giacomoni E, Pellegrino P. Herbal remedies and their possible effect on the GABAergic system and sleep. Nutrients. 2021;13(2):530. Shafiee M, Arekhi S, Omranzadeh A, Sahebkar A. Saffron in the treatment of depression, anxiety and other mental disorders: current evidence and potential mechanisms of action. J Affect Disord. 2018;227:330–337. Mehri S, Razavi BM, Hosseinzadeh H. Safety and toxicity of saffron. In: Koocheki A, Khajeh-Hosseini M, eds. Saffron. Woodhead Publishing; 2020:517–530. Kell G, Rao A, Beccaria G, Clayton P, Inarejos-García AM, Prodanov M. affron® a novel saffron extract (Crocus sativus L.) improves mood in healthy adults over 4 weeks in a double-blind, parallel, randomized, placebo-controlled clinical trial. Complement Ther Med. 2017;33:58–64.

When Eating Feels Like a Minefield: A Story of MCAS, Ketotifen, and Low-Dose Naltrexone By Yoon Hang Kim, MD, MPH Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician 🎥 Watch the short version: MCAS, Ketotifen & LDN — a client story For people living with mast cell activation syndrome (MCAS), eating can feel like a minefield. A food that was fine last month triggers flushing, hives, gut pain, or brain fog today. Over time, many people respond the only way that feels safe: they eliminate. First the obvious triggers, then the suspicious ones, then anything uncertain — until the "safe list" has shrunk to a handful of foods and mealtimes are ruled by fear rather than nourishment. I want to share a story from my practice about how the right combination — introduced slowly and carefully — made a remarkable difference for one client. And, just as importantly, what that story does and doesn't mean for anyone else navigating MCAS. A Shrinking Plate One of my clients with MCAS had become extremely limited in the foods they could tolerate. This is one of the most distressing places an MCAS journey can lead. Beyond the nutritional concerns, there is a psychological weight to it: every meal becomes a risk calculation, social eating disappears, and the world gets smaller. When someone arrives at this point, my goal is never to find a miracle. It is to find traction — some stabilization of the mast cell system that gives the body room to expand again. The Combination: Ketotifen + LDN For this client, we carefully introduced two medications together: Compounded ketotifen. Ketotifen is an older antihistamine with a second, less widely known property: it acts as a mast cell stabilizer, helping to reduce the release of histamine and other inflammatory mediators at the source rather than just blocking their effects downstream (Grant et al., 1990). In the United States it is not commercially available as an oral tablet, so it is typically prepared by a compounding pharmacy, which also allows very gradual dose titration — something MCAS clients often need. Low-dose naltrexone (LDN). At low doses, naltrexone appears to act quite differently than at standard doses, modulating glial cells and inflammatory signaling in ways that have made it a subject of growing interest for chronic inflammatory and pain conditions (Younger, Parkitny & McLain, 2014). In my practice, LDN has been a foundational tool for many clients with MCAS, autoimmunity, and chronic pain — always started low and adjusted patiently. The result for this client? Over time, they were able to tolerate a much wider variety of foods. Meals stopped being a minefield and started being meals again. The Important Part: There Is No Universal Protocol Here is what I most want readers to take from this story — and it is not "ketotifen plus LDN treats MCAS." MCAS treatment is highly individualized. The condition itself is heterogeneous: mast cells can misbehave in different ways in different people, and triggers, mediators, and comorbidities vary enormously from one person to the next (Molderings et al., 2011). There is no single medication, dose, or protocol that works for everyone. What produced a breakthrough for this client may do little for another — and something entirely different may be that person's key. In my experience, progress in MCAS usually comes from a few unglamorous principles: Go slowly. Start one change at a time, at low doses, so the body — and the clinician — can tell what is actually happening. Adjust carefully. Titration in MCAS is a craft. Sensitive systems often need smaller steps than standard dosing guides suggest. Let the body vote. Symptom response, not protocol adherence, guides the next step. Expand, don't just restrict. The goal of stabilization is to widen the safe list again — restriction is a temporary shelter, not a destination. Why This Is Personal After years of seeing MCAS both personally and professionally, I've learned that individualized care matters enormously. Behind every shrinking food list is a person who has usually been dismissed, misdiagnosed, or told their symptoms don't fit a pattern. They fit a pattern — just not a common one. Taking that pattern seriously, and working through it one careful step at a time, is where recovery begins. References Grant SM, Goa KL, Fitton A, Sorkin EM. Ketotifen: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in asthma and allergic disorders. Drugs. 1990;40(3):412–448. Younger J, Parkitny L, McLain D. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clinical Rheumatology. 2014;33(4):451–459. Molderings GJ, Brettner S, Homann J, Afrin LB. Mast cell activation disease: a concise practical guide for diagnostic workup and therapeutic options. Journal of Hematology & Oncology. 2011;4:10. Important: This article is for educational purposes only and does not constitute medical advice. MCAS is a complex condition, and treatment decisions — including the use of ketotifen or low-dose naltrexone — should always be made in partnership with a qualified healthcare professional who knows your individual situation. About Dr. Kim Dr. Yoon Hang "John" Kim is a board-certified physician with over 20 years of experience in integrative medicine. He completed his fellowship training under Dr. Andrew Weil at the University of Arizona and holds board certifications in Preventive Medicine as well as certifications in medical acupuncture and integrative & holistic medicine. He specializes in low-dose naltrexone (LDN) therapy, autoimmune conditions, chronic pain, integrative oncology, fibromyalgia, chronic fatigue syndrome, MCAS, and mold toxicity. Dr. Kim is the author of three books and more than 20 peer-reviewed articles. Professional: www.yoonhangkim.com | Clinical: www.directintegrativecare.com Yoon Hang Kim MD | www.directintegrativecare.com | 📞 (210) 981-6106 Follow for more on MCAS, low-dose naltrexone, functional medicine, and integrative medicine. #MCAS #MastCellActivationSyndrome #LowDoseNaltrexone #LDN #Ketotifen #FunctionalMedicine #IntegrativeMedicine #ChronicIllness #MastCells

Functional Medicine in San Antonio: A Root-Cause Approach with Yoon Hang Kim, MD, MPH Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician If you've spent years cycling through specialists, tests, and prescriptions — and you still don't feel well — the problem may not be you. It may be the model of care. Conventional medicine excels at acute crises, but chronic, complex illness often demands a different question: not "What is the diagnosis?" but "Why is this happening in the first place?" That question is the foundation of functional medicine, and it's the question Yoon Hang Kim, MD, MPH has spent more than two decades answering for clients with conditions that don't fit neatly into a fifteen-minute visit. Why Root Cause Matters Symptoms are signals, not the disease itself. Fatigue, brain fog, chronic pain, digestive distress, and recurring inflammation are downstream effects of underlying imbalances — immune dysregulation, hormonal disruption, gut dysfunction, environmental exposures, or chronic stress physiology. Suppressing the signal without addressing the source is why so many people feel stuck. Functional medicine works differently. It examines how your body's systems interact, then builds a plan around your biology, history, and life — not a protocol designed for the average patient who doesn't actually exist. Who This Approach Serves Best Dr. Kim's practice focuses on the conditions where root-cause medicine offers the most leverage: Autoimmune conditions — including low-dose naltrexone (LDN) therapy, an area where Dr. Kim has published and lectured extensively Mast Cell Activation Syndrome (MCAS) and complex multi-system illness Fibromyalgia and chronic fatigue syndrome Chronic pain — integrating medical acupuncture (UCLA certification) with modern pharmacology Mold toxicity and environmental illness Integrative oncology support — care alongside, never instead of, your oncology team What Working with Dr. Kim Looks Like Time, first. The practice is deliberately capped at a small number of active clients. That structural choice means consultations are unhurried, follow-up is real, and your case gets the sustained attention complex illness requires. This isn't a marketing claim — it's how the practice is built. A thorough investigation. Your first visit involves a detailed health history and, where appropriate, advanced testing to identify hidden drivers: inflammation markers, hormonal patterns, gut dysfunction, or nutrient deficiencies. A personalized, evidence-informed plan. Nutrition, targeted supplementation, stress physiology work, and conventional treatments when they're the right tool. Integrative medicine is not alternative medicine — it's using the full toolkit, judiciously. A partnership. You are the central actor in your own recovery. Dr. Kim's role is to bring twenty-plus years of clinical judgment to your side of the table — and to adjust the plan as your body responds. Why Membership-Based Care Changes Everything Most of what frustrates people about healthcare — rushed visits, surprise bills, months-long waits, playing phone tag through a portal — isn't caused by bad doctors. It's caused by the insurance-driven volume model, where a physician must see 25–30 patients a day to keep the lights on. Membership-based direct care removes that constraint entirely. Here's what that means for you in practice: Time that matches the complexity of your case. With the practice capped at 99 active clients — compared to the 2,000–2,500 a typical insurance-based practice carries — visits are as long as your situation requires. Complex illness cannot be untangled in twelve minutes. Direct access to your physician. Questions between visits go to Dr. Kim, not a triage queue. When you're adjusting an LDN dose or managing an MCAS flare, that responsiveness isn't a luxury — it's clinically meaningful. Complete price transparency. A flat monthly membership and a published fee schedule. No surprise bills, no coding games, no wondering what a visit will cost. No insurance middleman in clinical decisions. Treatment plans are built on what your case needs — not on what a payer will authorize. That independence is precisely what makes genuine root-cause work possible. Continuity and telemedicine convenience. Care continues wherever you are in Texas, with licensure across six states for clients who travel or relocate. Your physician knows your full story because he's the one who's been following it. For San Antonio clients managing chronic conditions, this model often costs less than the out-of-pocket total of copays, deductibles, and lost time in a conventional system — while delivering a fundamentally different level of attention. Experience You Can Verify Credentials matter when you're trusting someone with a complex case. Dr. Kim completed fellowship training in integrative medicine at the University of Arizona under Dr. Andrew Weil, is board-certified in Preventive Medicine and in Integrative & Holistic Medicine, and has held leadership roles including Medical Director of Integrative Oncology at Miami Cancer Institute and Enterprise Medical Director at Optum. He founded and ran Georgia Integrative Medicine for a decade, has authored three books and more than twenty peer-reviewed articles, and now serves clients in Texas — including the San Antonio area — through www.directintegrativecare.com. Taking the First Step Chronic illness rewards preparation and boldness in equal measure. If you're ready to stop managing symptoms and start investigating causes: Review the membership tiers and published fee schedule at www.directintegrativecare.com — everything is transparent before you commit Schedule an initial consultation and bring your full story — prior records, failed treatments, and all Expect a genuine investigation, not a quick fix — and a physician who will tell you honestly what integrative medicine can and cannot do for your situation Because membership is capped at 99 active clients, enrollment depends on current availability. If a spot is open when you're ready, that timing works in your favor. Your health story isn't finished. Sometimes it just needs a better editor. About Dr. Kim Dr. Yoon Hang "John" Kim is a board-certified physician with over 20 years of experience in integrative and preventive medicine. He completed his fellowship at the University of Arizona under Dr. Andrew Weil and holds certifications in preventive medicine, medical acupuncture, and integrative & holistic medicine. Dr. Kim specializes in low-dose naltrexone (LDN) therapy, autoimmune conditions, chronic pain, integrative oncology, fibromyalgia, chronic fatigue syndrome, MCAS, and mold toxicity. He is the author of three books and more than 20 peer-reviewed articles. Professional: www.yoonhangkim.com | Clinical: www.directintegrativecare.com